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Abstract 
The long term goal of this study was to develop towards a non-genetically modified organism 
(non-GMO) as human mucosal vaccine against tuberculosis (TB), using lactic acid bacteria 
(LAB) as a delivery vehicle for surface anchored antigen-containing proteins. LABs have 
characteristics that make them excellent as delivery vehicle for vaccines: they are not associated 
with pathogenesis, they have been used in the food industry for centuries, they have known 
probiotic effects, and they are natural inhabitants of the human gastrointestinal tract (GIT) where 
they interact with immune cells in the mucosal surfaces. Additionally, LABs have the ability to 
survive the tough environmental conditions following an oral administrated vaccine, e.g. as the 
low pH values ranging from 1.8–3. 
In this study, the widely studied antigens Ag85B and ESAT6 from the TB causative agent 
Mycobacterium tuberculosis (Mtb) were fused together to a 41 kDa protein, and various anchors 
were attached. The proteins were expressed in, and extracted from E. coli strains before being 
anchored to Lactobacillus spp and B. subtilis. The anchors used were peptidoglycan binding 
domains with a Lysine Motif (LysM domain). The two anchoring domains were tested; a single 
LysM domain from the L. plantarum protein Lp_3014 (extracellular transglycosylase), and the 
double LysM domains from the L. plantarum protein Lp_2162 (muropeptidase). To test the 
stability of the resulting constructs, L. plantarum loaded with recombinantly produced LysM 
containing Ag85-ESAT6-DC were subjected to 2% bile and pH values ranging from 1.8–6.5, 
showing that the antigen-containing proteins were able to resist degradation when incubated at 
low pH. This indicated that the protein-loaded bacteria would be capable to survive incubation at 
low pH values. However, the co-incubation of bile and the negative control (L. plantarum not 
displaying Ag85-ESAT6-containing protein) were revealing positive signals, thus implying that 
the positive signals achieved from co-incubating the protein-loaded bacteria and 2% bile could 
contain false positives, when analyzed by western blotting and flow cytometry. Incubation in bile 
should, therefore, be repeated using another method.  
Previous studies have shown that LAB displaying the Ag85-ESAT6-DC on their surfaces creates 
promising immune responses. The current results, thus provide a promising starting point towards 
achieving the final goal; developing a non-GMO vaccine against TB, that elicits better and longer 
lasting immune responses than the now available BCG-vaccine. 
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Sammendrag 
Det langsiktige målet for denne studien var å utvikle en ikke-genetisk modifisert organisme 
(ikke-GMO) til å bruke som en menneskelig vaksine mot tuberkulose, ved hjelp av 
melkesyrebakterier som overleveringsagenter for overflatefestede proteiner som inneholder 
antigenene. Melkesyrebakterier har egenskaper som gjør dem svært godt egnet som 
overleveringsagenter for vaksiner; de er ikke assosiert med patogenesitet, de har vært brukt i 
matindustrien i århundrer, de har kjente probiotiske effekter i tillegg til deres naturlige 
tilstedeværelse i det humane mage-tarm systemet, der de interagerer med immuncellene i 
slimhinnene. Melkesyrebakterier har i tillegg evnen til å overleve det utfordrende miljøet som 
følger en oralt administrert vaksine, f.eks. lave pH-verdier, i området 3–1.8.  
I denne studien ble de bredt-diskuterte antigenene Ag85B og ESAT6 fra tuberkulosens utløsende 
agent, Mycobacterium tuberculosis (Mtb), sammensatt til et protein på 41 kDa tilsatt forskjellige 
ankere. Proteinene ble uttrykt i og ekstrahert fra E. coli-stammer før de ble ankret til 
Lactobacillus spp og B. subtilis. Ankerene som ble brukt var peptidoglucan bindende domener 
med et Lysine Motif (LysM domene). De to ankringsdomenene som ble testet; et enkelt LysM 
domene fra L. plantarums protein Lp_3014 (extracellulær transglykosylase), og det doble LysM 
domenene fra L. plantarums Lp_2162 (muropeptidase). For å teste stabiliteten til det resulterende 
konstruktet, ble L. plantarum ladet med det rekombinante produserte LysM inneholdende 
Ag85B-ESAT6-DC følgende inkubert i 2 % galle og pH-verdier som strekker seg fra 1.8–6.5. 
Dette viste at det antigen-inneholdende proteinet var i stand til å motstå degradering når den ble 
inkubert i lave pH-verdier. I motsetning viste den negative kontrollen (L. plantarum, ikke ladet 
med det antigeninneholdende proteinet), når inkubert i galle, positive signaler. Dette gav en 
indikasjon på at det oppnådde positive resultatet av den inkuberte proteinladede bakteriecellen i 
galle, muligens inneholdt falske positiver etter å ha blitt analysert med western blotting og 
væskestrømscytometri. Inkubering i galle burde derfor gjentas ved å bruke en annen metode.  
Tidligere studier har vist at melkesyrebakterier ladet med antigenet A685B-ESAT6-DC på 
celleoverflaten oppnådde lovende immunresponser. De nåværende resultatene gir et lovende 
startpunkt mot å oppnå det optimale målet: å utvikle en ikke-GMO vaksine mot tuberkulose, som 
fremprovoserer bedre og lengre immunresponser enn den nå tilgjengelige BCG-vaksinen. 
IV 
 
Abbreviations 
2162-TB – the protein 2162-Ag85B-ESAT6-DC 
3014-TB – the protein 3014-Ag85B-ESAT6-DC 
BCG – Bacille Calmette-Guèrin  
BSA – Bovine Serum Albumine 
DC – Dendritic cells 
FITC – Fluorescein isothiocyanate  
GIT – Gastrointestinal tract 
GRAS – Generally regarded as safe 
LAB – Lactic acid bacteria 
LysM – lysin Motif domain 
MDR-TB – multidrug resistant tuberculosis  
Mtb – Mycobacterium tuberculosis 
NAG – N-acetylglucosamine 
NAM – N-actelymuramic acid 
Ni-NTA – Nikkel Nitrilotriacetic Acid  
PBS – Phosphate Buffered Saline  
PCR – The polymerase chain reaction 
SDS-PAGE – Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
TB – tuberculosis 
XDR-TB – Extensively drug-resistant TB
 
 
CONTENTS 
1. INTRODUCTION: ............................................................................................ 1 
1.1 Tuberculosis and the further development of MDR-TB and XDR-TB ............................. 1 
1.2 The almost one-century old Bacille Calmette-Guèrin vaccine .......................................... 2 
1.3 Lactic acid bacteria ............................................................................................................ 3 
1.3.1 Lactobacillus as a delivery vehicle ............................................................................ 3 
1.3.2 Bacillus subtilis as a delivery vehicle ........................................................................ 4 
1.4 The antigens of Mycobacterium tuberculosis used in this study ....................................... 5 
1.5 Anchoring heterologous proteins to vectors ...................................................................... 6 
1.5.1 The peptidoglycan layer ............................................................................................. 8 
1.5.2 Lysine Motif (LysM) domain ..................................................................................... 9 
1.6 Genetic modified organism ............................................................................................. 10 
1.7 The human mucosal immune system ............................................................................... 11 
1.7.1 Dendritic cells and the elicited immune response .................................................... 13 
1.8 The outline of this study .................................................................................................. 13 
2. MATERIALS ................................................................................................... 16 
2.1 Laboratory consumables ....................................................................................................... 16 
2.3  Chemicals ........................................................................................................................ 18 
2.4 Proteins, enzymes and related standard solutions ........................................................... 20 
2.5 Nucleotodes and DNA ..................................................................................................... 21 
2.6 Primers ............................................................................................................................. 21 
2.7 Bacterial and plasmids ..................................................................................................... 24 
2.8 Kits ................................................................................................................................... 26 
2.10 Buffers and solutions ....................................................................................................... 30 
3. METHODS ....................................................................................................... 32 
3.1 Growth of bacteria cultures ............................................................................................. 32 
3.2 Long term storage of bacteria .......................................................................................... 32 
3.3 Isolating plasmids from bacteria cultures ........................................................................ 33 
3.4 Genomic DNA isolation .................................................................................................. 34 
 
 
3.5 The polymerase chain reaction (PCR) ............................................................................. 35 
3.5.1 PCR reactions with Q5™ High-Fidelity DNA Polymerase ..................................... 36 
3.5.2 PCR with the VWR® Taq DNA Polymerase Master Mix ....................................... 37 
3.6 Agarose Gel Electrophoresis ........................................................................................... 38 
3.7 DNA purification and extraction from agarose gels ........................................................ 39 
3.8 Restriction enzyme digestion of DNA ............................................................................. 39 
3.9 Determination of DNA concentration ............................................................................. 40 
3.10 Ligation of DNA fragments ............................................................................................. 41 
3.11 Preparation of competent bacterial cells .......................................................................... 42 
3.11.1 Preparation of electro-competent Lactobacillus plantarum WCFS1 ....................... 42 
3.11.2 Preparation of chemically competent Escherichia coli TOP10 cells ....................... 43 
3.12 Electroporation of Lactobacillus plantarum WCFS1 ...................................................... 44 
3.13 Transformation of chemical competent Escherichia coli ................................................ 44 
3.14 Protein production Escherichia coli ................................................................................ 45 
3.15 Protein purification .......................................................................................................... 46 
3.16 Gel electrophoresis of proteins ........................................................................................ 48 
3.17 Concentrating proteins in a solution ................................................................................ 49 
3.18 Measuring protein concentrations ................................................................................... 50 
3.19 Recovery of proteins from inclusion bodies .................................................................... 50 
3.20 Gel Electrophoresis with Native acrylamide gels ............................................................ 53 
3.21 Anchoring LysM domain-containing proteins to gram positive bacteria ........................ 55 
3.22 Western blot analysis ....................................................................................................... 56 
3.22.1 SNAP i.d. immunodetection ..................................................................................... 57 
3.22.2 Chemiluminiscent detection of protein .................................................................... 59 
3.22.3 Stripping and re-probing the nitrocellulose membrane from western blot analysis ... . 
……………………………………………………………………………………………….60 
3.23 Detection of surface antigens using FITC-labelled secondary antibodies and flow 
cytometry .................................................................................................................................... 61 
3.24 Protein production in Lactobacillus plantarum ............................................................... 62 
3.25 Destructions of cells using glass beads ............................................................................ 63 
3.26 Prepare cells for freeze drying ......................................................................................... 64 
 
 
3.27 Lysozyme treatment ........................................................................................................ 65 
4. RESULTS ............................................................................................................ 66 
4.1 Intracellular production of 3014-TB and 2162-TB in Escherichia coli .......................... 66 
4.1.1 Construction of 3014-TB ......................................................................................... 66 
4.1.2 Construction of 2162-TB ......................................................................................... 68 
4.2 Protein expression ............................................................................................................ 69 
4.2.1 Intracellular expression of 3014-TB in Escherichia coli ......................................... 70 
4.2.2 Intracellular expression of 2162-TB in Escherichia coli ............................................... 74 
4.3 Purification of proteins from cell extracts of E. coli ....................................................... 75 
4.3.1 Purification of 3014-TB ................................................................................................. 75 
4.3.2 Purification of 2162-TB ................................................................................................. 79 
4.4 Anchoring of 3014-TB and 2162-TB to the cell surface of living bacteria .................... 81 
4.4.1 Incubating L. plantarum with 3014-TB proteins ........................................................... 81 
4.4.2 Unspecific interactions to the cell surface of Lactobacillus plantarum ................... 83 
4.4.3 3014-TB binds to a broader range of bacteria strains .............................................. 85 
4.4.4. 2162-TB anchored to the cell surface of Bacillus subtilis and Lactobacillus spp 
…………………………………………………………………………………………….…90 
4.5 Effect of low pH and bile on 3014-TB and 2162-TB ...................................................... 91 
4.5.1 3014-TB and 2162-TB after freeze drying and storage ................................................. 91 
4.5.2 L. plantarum cells displaying 3014-TB or 2162-TB, incubated in low pH values ........ 93 
4.5.3 L. plantarum cells displaying 3014-TB or 2162-TB, incubated in bile ......................... 94 
4.6 Expression of Lp_3014-TB and Lp_2162-TB in Lactobacillus plantarum .................... 96 
4.6.1 The construction of Lp_2162-TB and Lp_3014-TB ................................................ 96 
4.6.2 Lp_3014-TB and Lp_2162-TB displayed at Lactobacillus  plantarum surfaces 
………... .................................................................................................................................. 97 
5. DISCUSSION ...................................................................................................... 99 
5.1 Intracellular production of 3014-TB and 2162-TB in Escherichia coli .......................... 99 
5.2 Purifying 3014-TB and 2162-TB from Escherichia coli protein extract ...................... 100 
5.3 Anchoring 3014-TB and 2162-TB to the cell surface ................................................... 102 
5.4 Comparing the potential of 3014-TB and 2162-TB  to bind to cell surfaces of L. 
plantarum .................................................................................................................................. 104 
 
 
5.5 Comparisons of the constructs 2162-TB and 3014-TB ................................................. 105 
5.6 Comparing L. plantarum cells charged with Lp_3014-TB or Lp_2162-TB  to the cells 
charged with 3014-TB or 2162-TB .......................................................................................... 107 
5.7 Concluding remarks and future perspectives ................................................................. 108 
6. REFERENCES ................................................................................................. 110 
APPENDIX (A1–A7) ................................................................................................. i 
 
 
 
 
 INTRODUCTION 
1 
 
1. INTRODUCTION: 
Tuberculosis (TB) is a single infections agent causing the second highest mortality worldwide, 
after HIV/AIDS (WHO 2014). After the successfully developed BCG-vaccine, based on weak or 
dead Mycobacterium bovis, the general assumption was that TB no longer posted a threat. Latest 
researches have revealed 80% effective protection in children, when given the BCG-vaccine. 
However, this protective effect is lost after reaching 25 years of age, and vaccination at this age 
causes no measurable protection against TB (Andersen & Doherty 2005). Another urgent issue is 
the development of a multi-resistant TB (MDR-TB). The development of MDR-TB has started 
the race to market the next TB-vaccine, hopefully resulting in a better and longer lasting immune 
response (Velayati et al. 2009; Wang et al. 2013).  
The long-term goal of this study is to contribute to the development of a new non-GMO TB 
vaccine. This was done by exploiting two well-documented antigens from the causative agent of 
TB, Mycobacterium tuberculosis (Mtb). Using peptidoglycan anchors, the combined antigens 
were bound to harmless bacteria such as Lactobacillus spp. and B. subtilis, which hopefully could 
result in a non-GMO bacterial vaccine.  
 
1.1 Tuberculosis and the further development of MDR-TB and XDR-TB 
According to the World Health Organization tuberculosis (TB) fact sheet (WHO 2014), TB is a 
single infectious agent that causes the second highest number of mortality worldwide, after 
HIV/AIDS. In 2012, as many as 1.3 million people died from TB, and incidents are documented 
from all over the world, with the highest level of mortality in Asia.  
The causative agent of TB is Mycobacterium tuberculosis (Mtb), which spreads through the air 
and affects the lungs. Typical TB symptoms are weight loss, night sweats and coughing. The 
drug-sensitive TB can be treated with a six months antibiotic cure, using the most powerful and 
commonly used drugs (first line anti-TB drugs), isoniazid and rifampicin (WHO 2013). Increased 
use of poor quality anti-TB drugs has led to the development of a multi-resistant (MDR) Mtb, 
causing the MDR-TB. MDR-TB escalates the need for second lined anti-TB drugs, which is 
limited or not available.  
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Searching for MDR-TB cases, revealed a new type of resistant Mtb, causing extensively drug-
resistant TB (XDR-TB) and totally drug-resistant TB (TDR-TB) (Velayati et al. 2009; WHO 
2013), which are resistant to all second line anti-TB drugs. The negative development of MDR-
TB is difficult to control and the treatment equally difficult, because of the expensive and 
unavailable chemotherapy and second line anti-TB drugs. Importantly, one untreated and 
undetected individual could infect as many as 15 contacted individuals per year (WHO 2009).  
 
1.2 The almost one-century old Bacille Calmette-Guèrin vaccine 
Mycobacterium tuberculosis (Mtb) spread quickly through the air and infects large populations of 
people, causing TB, MDR-TB and XDR-TB. The treatment is expensive, limited and unavailable 
in some countries, making prevention against Mtb infection the best alternative to defeat new TB 
cases (Ottenhof & Kaufmann 2012). The best precaution available today is the Bacille Calmette-
Guèrin (BCG) vaccine, which consists of weak or dead Mycobacterium bovis. In 80% of the 
cases, the BCG vaccine results in significant TB protection in infants, but the protective effect 
weakens in individuals reaching 25 years of age (Andersen & Doherty 2005). In addition, there is 
no protective effect measured after vaccination as adults. Despite limitations, the BCG vaccine is 
the only alternative available on the market today, and WHO considers BCG as an important tool 
for the treatment of TB, until an improved vaccine against TB is available at the market. 
Of the 55 species of the genus Mycobacterium, half of these are known to cause diseases in 
humans (Ottenhof & Kaufmann 2012). Little is known about the interactions between host and 
pathogen, which precludes a targeted vaccine development and leads to a broad range of new 
vaccine approaches. Today, at least 15 new vaccine candidates are in the development pipeline, 
one of which was based on improving the already existing BCG vaccine by co-administration of 
dominant antigens such as Ag85B (Ottenhof & Kaufmann 2012). Other approaches include 
subunit vaccines, i.e. vaccines where several antigenic proteins are combined to elicit stronger 
immune responses (Ottenhof & Kaufmann 2012). An upcoming approach, not yet in the TB 
vaccine development pipeline, is the use of lactic acid bacteria (LAB) as a delivery vehicle for 
vaccines (Wells 2010; Wells & Mercenier 2008).  
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1.3 Lactic acid bacteria 
Lactic acid bacteria (LAB) are gram positive bacteria with low GC content, and are characterized 
by their major product from the carbohydrate fermentation process, lactic acid. LABs are found 
in a broad range of food fermentation products from dairy, meat and vegetable, where they 
produce lactic acid to lower the food’s pH and prevents spoilage (Daniel et al. 2011). LABs are 
not associated with pathogenic effects; some LAB genera, as Lactobacillus have a “Generally 
Regarded As Safe” status (GRAS), and are considered as probiotics. Probiotics are evaluated to 
give health benefits to the consumer, according to the Food and Agriculture Organization of the 
United Nations (FAO) and WHO (FAO/WHO 2001). Several strains of Lactobacillus are natural 
habitants of the human and animal’s gastrointestinal tract (GIT), and have the ability to survive 
transportation through the GIT.  
 
1.3.1 Lactobacillus as a delivery vehicle 
The use of Lactobacillus as a delivery vehicle for orally administrated vaccines is conceivable 
because of their GRAS status, long record of safe consumption, food fermentative properties, and 
their ability to survive and even persist in the gastrointestinal tract (GIT). The mucosal surfaces 
in the GIT are the main entry sites for pathogens to enter into the body, and are therefore packed 
with immune cells (Lea 2006). To succeed as a delivery vehicle, the cells must survive the GIT 
environments and interact with the mucosal surfaces, which are in fact properties Lactobacillus 
possesses (Wells & Mercenier 2008). The mucosal route has the potential to stimulate both a 
systemic and mucosal immune response, by interacting with the inductive site of the mucosal 
immune system (see section 1.7 and Figure 1.4 for more details).  
Recombinant lactic acid bacteria (rLAB) can be engineered to express targeting molecules or 
adjuvants, and has given promising secretory IgA- and antigen specific-immune responses 
(Daniel et al. 2011). rLAB, even though strain dependent, have revealed the potential to elicit 
immune responses (Wells & Mercenier 2008), and the possibility to sustain stress factors as bile 
and low pH values (Daniel et al. 2011; Kõll et al. 2008). These are important properties to 
possess when used as a delivery vehicle. The elicited immune response depends on the rLAB 
genera used, the antigen produced and the disease investigated (Daniel et al. 2011).  
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Lactobacillus engineered to produce and deliver antigens are one of the most commonly used 
LAB genera for mucosal vaccination.  
The genus of Lactobacillus consists of more than 60 species with varying fermentation products, 
GC content and metabolisms (Wells & Mercenier 2008). This gives a broad range of alternatives 
used as a delivery vehicle. Many aspects need to be considered before the proper Lactobacillus 
strain is chosen as the delivery vehicle. Examples are: colonization abilities in human cavities 
(mouth, stomach, vaginal, small or large intestine), if they are “commercial” strains (daily used in 
industry, in the fermentation process) and assesses immune-adjuvant- and immune-stimulating 
capacities (Daniel et al. 2011). How cells are produced also affects the elicited immune response; 
in an in vitro study using L. plantarum as a delivery vehicle for antigens, only L. plantarum 
harvested in stationary phase, in contrast to exponential phase, gave a molecular response (Daniel 
et al. 2011). To elicit the proper immune response, delivery vehicles need to present the antigens 
at the proper inductive site (correct location) (Kim et al. 2012), and avoid immune tolerogenic 
environments at the mucosal surfaces. How immune cells are targeted and how they respond also 
affect the resulted immune response (Manicassamy & Pulendran 2011). 
In an exciting review by Wells (2010), 27 different targeting vaccines using LAB as a delivery 
vehicle have reached the stage of animal model testing. One of which, uses Lactobacillus 
acidophilus as a delivery vehicle for the protective antigen (PA), yielding protection in mice 
against Bacillus anthreacis (Mohamadzadeh et al. 2009; Wells 2010).  
 
1.3.2 Bacillus subtilis as a delivery vehicle 
Other bacteria than LAB may also be considered as delivery vehicles and one of these are B. 
subtilis. B. subtilis is a gram positive bacterium, suitable as delivery vesicle in vaccine 
development against TB, due to the following advantages; B. subtilis is not associated with 
pathogenic activity, they are low in costs, thermo-stable, non-invasive and easily genetically 
manipulated (Amaguni & Tzipori 2012). B. subtilis is probiotic labeled and proven to be safe to 
humans (Cutting 2010). B. subtilis and B. subtilis’ endospores have been used as antigen delivery 
vehicles in the human gut (Amaguni & Tzipori 2012), and researches have revealed the spore’s 
ability to germinate in the gastrointestinal tract (GIT), providing an additional route for antigen 
delivery.  
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The delivery system (using B. subtilis or the endospore of B. subtilis) makes a better vaccine than 
the purified antigen alone, since the antigen displayed at the cell is presented directly to the 
immunization sites and generates a stronger immune response (Amaguni & Tzipori 2012). 
Similar reasoning applies to other bacterial delivery systems, including LAB. 
 
1.4 The antigens of Mycobacterium tuberculosis used in this study  
The sequencing of the Mycobacterium tuberculosis (Mtb) genome in combination with the 
progress in molecular studies of the bacterium resulted in the discovery of a broad range of 
antigens.  In the following processes the most promising and relevant antigens from Mtb were 
combined to create a protein more suited to elicit a better immunity than the BCG-vaccine. Two 
of the most tested and promising antigens of Mtb are Ag85B and ESAT6, which are secreted 
upon infection (Cole et al. 1998).  
The primary antigen discovered in vaccine-development was antigen 85B (Ag85B), and the first 
to be used in animal testing (Horwitz et al. 2000). A higher protective immunity against Mtb 
aerosol was discovered for recombinant BCG (rBCG) expressing and secreting Ag85B encoded 
protein, in contrast to the normal BCG (Horwitz et al. 2000). The Ag85 family (Ag85A, B and C) 
encodes for abundant secretory proteins of mycolyl transferases which takes part in cell wall 
mycolic acid synthesis. The family members are closely related, but only Ag85A and B are 
known to elicit human T-cell response (Takatsu & Kariyone 2003). 
Another early identified T-cell targeted antigen was the Early Secreted Antigenic Target-6 
(ESAT6) antigen, which unfortunately revealed no inherited immunity towards TB (Brandt et al. 
1996). ESAT6 is part of a 23 membered multigene family in Mtb, and encodes a small (6 kDa) 
immunogenic protein. Expressed and purified ESAT6 as a vaccine gave a lower specific antigen 
response (Immunoglobin G, IgG) than Ag85B and BCG (Horwitz et al. 2000; Huygen et al. 
1996; Kamath et al. 1998; Li et al. 1999). ESAT6 needed a stronger adjuvant, and combined with 
Ag85B, the enhanced immune response was stronger (Dietrich et al. 2006; Doherty et al. 2004). 
Ag85B-ESAT6, a 41 kDa fused protein, resulted in strong immune responses when given as a 
vaccine; either as DNA or as the encoded protein (Dietrich et al. 2006). The fused protein results 
in much higher protection in animal models (mouse and guinea pig) than the antigens given 
individually (Doherty et al. 2004). The fused protein also promotes high immune responses 
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against TB in mouse, guinea pig and non-human primate models (Langermans et al. 2005; Olsen 
et al. 2001; Olsen et al. 2004). Several other promising antigens are currently under investigation, 
including Rv2029c, RV1733 and RV0315 (Byun et al. 2012; Sutherland et al. 2013).  
 
1.5 Anchoring heterologous proteins to vectors 
As discussed in section 1.3.1 and 1.3.2, Lactobacillus and B. subtilis has many advantages as 
delivery vehicles, and are therefore often used as delivery vectors. Heterologous proteins can be 
displayed at the cell surface through various types of cell wall anchoring. The anchoring between 
the heterologous protein and the delivery vehicle needs to be as specific as possible, to ensure the 
attachment to a proper nonpathogenic bacterium. The protein must avoid degradation at the cell 
surface, and be presented as a structural and functional protein to immune cells in order to elicit 
an immune response.  
Secreted proteins that anchor to the cell wall or membrane in gram positive bacteria can be 
divided into four main groups, using different anchoring mechanisms (Figure 1.1): 
1. Transmembrane proteins  
2. Lipoproteins 
3. LPxTG-anchored proteins  
4. Non-covalent cell wall binding proteins  
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Figure 1.1: Illustration of different proteins secreted by L. plantarum, anchored to the cell 
wall or membrane. The predicted number of proteins secreted by L. plantarum containing each 
anchoring domain is given in parentheses. Furthest to the left in the picture are two 
transmembrane proteins, N- and C-terminally anchored to the cell membrane. Third from the left 
is the membrane-anchored lipoprotein, through its lipobox domain. Furthest to the right, are the 
cell wall anchors; LysM domains (non-covalently anchored), and the LPxTG (covalently 
anchored). For more information see the text. The picture is taken from (Boekhorst et al. 2006). 
 
Transmembrane proteins are a large group of proteins that anchors either N- or C-terminal to the 
membrane in gram positive bacteria (Figure 1.1). The N-terminally anchored proteins lack the 
cleavage site in the signal peptide and are intact upon anchoring, while C-terminally anchored 
proteins are cleaved before anchored (Kleerebezem et al. 2003). Lipoproteins contain a C-
terminal lipobox motif. The motif is recognized by an enzyme, that covalently anchors the mature 
proteins to the long-chain fatty acids that are inserted into the cell membrane, through a thioehter 
linkage (Figure 1.1) (Kleerebezem et al. 2003). LPxTG are a well-known group of proteins that 
are characterized by their C-terminal LPxTG domain, which are recognized by the sortase (srtA) 
enzyme. Upon recognition, srtA cleaves the domain and covalently anchors the protein to the 
peptidoglycan (Kleerebezem et al. 2003). Non-covalent cell wall binding proteins employ cell-
wall binding domains such as the choline-binding domains, SH3 domains, SLH domains and 
LysM domains. The Lysine Motif (LysM) domains are well known peptidoglycan binding 
domains (Kleerebezem et al. 2003). 
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1.5.1 The peptidoglycan layer  
The peptidoglycan layer is a thick and complex layer surrounding gram positive bacteria. The 
peptidoglycan layer varies in ultrastructure, and comprises a complex multilayered network 
containing peptidoglycan, polysaccharides and either teichoic acid or teichuronic acid (Ghuysen 
1986). The sugar units in peptidoglycan are N-acetylglucosamine (NAG) and N-acetylmuramic 
acid (NAM), and the repeating unit in the polysaccharide part is a disaccharide of these two 
sugars. NAG and NAM containing polysaccharides are cross-linked by peptide bridges (Ghuysen 
1986). The peptide cross-linking bridges can vary chemically and may be branched (Figure 1.2).  
 
 
Figure 1.2: Schematic overview of the general peptidoglycan structure. The NAM and NAG 
monomers constitute glycan strains, also called the carbohydrates “backbones” of the structure 
(nude/purple). These are linked together by cross-bridged amino acids (blue). Side chains arise 
from the side chain amino acids (green), which appears as tetrapeptide chains. The picture is 
taken from (Biocourses 225). 
 
It is the structural and compositional changes in the peptidoglycan layer (Figure 1.2) that 
contributes to the variation found in the cell walls of gram positive bacteria. Anchoring domains, 
such as LysM domains (see section 1.5.2) binds to these varying structures, possibly resulting in 
a specific bonding between protein and bacteria.  
 INTRODUCTION 
9 
 
1.5.2 Lysine Motif (LysM) domain  
The LysM domain is a specific protein domain that binds non-covalently to peptidoglycan and 
chitin. LysM domain-containing proteins are found in eukaryotes and prokaryotes, and a Pfam 
search on LysM domain results in more than 4000 hits (Buist et al. 2008). LysM domains are 
usually 44–65 amino acid residues in length, and multiple copies are separated by a conserved 
linker region, called PST (rich in proline, serine and threonine) (Ohnuma et al. 2007). The PST 
region is rather flexible and can vary in both length and composition. LysM domains can be 
located at the N-terminus or C-terminus of a protein, but are also found at internal positions. 
There is a broad range of LysM-containing proteins in nature, occurring for example in proteins 
involved in pathogenesis, bacterial cell wall-degrading enzymes, and proteins involved in plant 
recognition of symbiotic bacteria (Bosma et al. 2006). It has previously been pointed out that 
LysM domains could be used to anchor heterologous proteins to gram positive bacteria, for both 
medicinal and industrial purposes (Bosma et al. 2006).  
LysM domains are most likely to interact with NAG monomers in the peptidoglycan layer (see 
section 1.5.1 and Fig. 1.2), because, by increasing the amount of added NAG monomers in the 
peptidoglycan through the elongation of carbohydrate ligands, increases the binding-affinity 
towards LysM (Buist et al. 2008; Wong et al. 2013). LysM domains binding-sites show 
conservation across phyla, and neither plant nor bacterial LysM-containing proteins discriminate 
between NAG-containing (hetero)polymers in peptidoglycan and the NAG homopolymer chitin 
(Wong et al. 2013). Additionally, increasing the number of LysM domains in a protein, 
proportionally increases the binding affinity towards peptidoglycan and chitin polymers (Wong et 
al. 2013).  
L. plantarum is predicted to encode 223 extracellular proteins (some of which are shown in 
Figure 1.1), where 10 of these are predicted to contain one or more copies of the LysM domain 
(Boekhorst et al. 2006). Two of these proteins containing LysM domains; are the single LysM 
containing protein Lp_3014 and the double LysM domain containing protein Lp_2162 (Fig. 1.3) 
(Boekhorst et al. 2006). 
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Figure 1.3: Illustrates two of the L. plantarum WCSF1 cells’ extracellular proteins that 
contain LysM domain. The LysM domains are marked using red boxes and are located in the N-
terminal of the proteins.  The proteins differ in both sizes, expected functions and the number of 
LysM domains. See text for more information. The Figure is taken and altered from (Boekhorst et 
al. 2006). 
 
Lp_3014 is predicted to be extracellular transglycosylase, whereas Lp_2162 is predicted to be 
muropeptidase (Boekhorst et al. 2006). The binding abilities of the LysM anchors are highly 
dependent on the proteins they are part of (Bosma et al. 2006), and some LysM domains even 
reveal strain specific binding affinities (Navarre & Schneewind 1999). The single and double 
LysM anchors from Lp_3014 and Lp_21621, respectively, were used in the present study to 
discover the better anchor for anchoring the heterologous protein to the peptidoglycan layer 
surrounding the gram positive bacterium.  
 
1.6 Genetic modified organism  
The use of genetic modified organism (GMO) in Norway has been administrated through the 
gene-technology law since its origination in 1993 (lastly altered in 2001) (Lovdata 2013). The 
law corresponds to the EU-regulations on GMO-use with some differences. In Norway a release 
of GMOs to the market has to be useful and in line with the principle of sustainable development. 
In addition Norway looks at each situation (product) individually, and Norwegians think of 
themselves as stricter than the EU regulations dictate (Biotekforum 2014). By this law; GMO is 
defined as plants, animals and microorganisms that have their genetic composition altered 
through gene- or cell-technology (Lovdata 2013). The objective function (§ 2) of the law states 
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(Lovdata 2013); legal provisions on genetically modified organisms also apply to substances and 
products consisting of or containing genetically modified organisms. 
There is a natural skepticism towards GMO, mostly because of the unknown effects following the 
use or release of GMO in nature (The non-GMO project 2011). GMOs are banned in 60 
countries, including Japan, Australia and the EU members. Due to skepticism and regulations, 
killed lactic acid bacteria (LAB) in vaccine delivery are considered advantageous over living 
LAB (Wells 2010; Wells & Mercenier 2008). Development of a non-GMO LAB-based vaccine 
will have an advantage; this may be achieved by loading non-GMO LAB with externally added 
vaccine molecules that contain anchoring domains such as LysM domains.  
 
1.7 The human mucosal immune system   
For a vaccine to elicit an immune response in the individual ingesting it, the vaccine must interact 
with the immune cells in the mucosal surfaces. The main entry into the body is through the 
mucosal surfaces covering the respiratory tract, the digestive tract and the urinary tract (Lea 
2006). Mucosal surfaces are therefore packed with immune cells that must distinguish between 
pathogens, nutrition and the natural microflora of the gut. The most exposed being the digestive 
tract stretching from pharynx to the rectum, and the broad range of tasks corresponds to the 
varying immune systems found in these areas, whereas the most known is the gastrointestinal 
tract (GIT) (Lea 2006). The GIT stretches as a continuous long tube from mouth to colon, lined 
with mucus membrane (Richaud-Patin et al. 2005). Both the adaptive and the native immunity is 
present at the mucosal surfaces in the intestine, including particular structures as the payer’s 
patches, epithelia and physical barriers (Lea 2006; Richaud-Patin et al. 2005) Antigens presented 
by live bacteria will interact with the immune cells located in these structures to elicit an immune 
response (Figure 1.4). 
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Figure 1.4: The immune defense line in the mucosal surfaces located in the intestine. The 
epithelial cells form a physical barrier between the gut lumen and lamina propria. Antigens in the 
lumen are picked up by M-cells or dendritic cells (DC), and are transferred into the payer patches 
where they meet T-cells. The intact antigen is then transferred to professional antigen-presenting 
cells (APC) which further activates the mesenteric lymph nodes. The activated lymphnodes 
migrate to the mesenteric lymph node, resulting in the started immune response. See text for 
more information. Figure modified from (Mowat 2003). 
 
The physical barrier in the intestinal immune system consists of the gut epithelium, with tight 
junctions in between, only letting 2 kDa molecules pass. Beneath the epithelium line is the highly 
organized lymphoid tissue, with the common name GALT (Gut-associated lymphoid tissue). 
GALT is an organized tissue including the payer’s patches, the lymphoid follicles and the 
mesenteric lymphnodes (Richaud-Patin et al. 2005). Antigens interacting with the mucosal 
surfaces in the intestine are either taken up by dendritic cells (DC) or Microfold (M)-cells. M-
cells interact and activate the professional antigen-presenting cells (APC), as the DC and 
macrophages. Activated APC interact and activate strategically placed B- and T-cells in the 
payer’s patches (Fig. 1.4). Any activated immune cells can migrate to mesenteric lymphnodes 
and induce an immune response (Figure 1.4). 
 
DC 
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1.7.1 Dendritic cells and the elicited immune response  
Dendritic cells (DC) are found in an immature state in most tissues throughout the body, 
especially in T-cell rich areas (T-cells only recognize antigens processed and presented by 
antigen-presenting cells, APC). DC and B-cells are examples of professional APC, which ingest 
intruding microbes or particles by endocytosis, process these and present the antigens on their 
cell surfaces attached to major histocompatibility complex (MHC) class II molecules (Lea 2006). 
The resulting immune response depends on the processing of antigens, the antigen-presenting 
cell-type, and the type/amount of adhesion and co-stimulating molecules between activated APC 
and T-cell (Lea 2006). These variations determine the interaction with T-cells and subsequent T-
cell activation (Lea 2006).   
Depending on DC-surfaced expressed markers, three subpopulations of DC are found in the gut 
(Richaud-Patin et al. 2005), named myleoid, lymphoid and the double negative. DCs either 
receive antigens from M-cells or capture antigens in the gut lumen through their elongations 
between epithelial cells. Immune responses elicited by DC depends on how the DC interact with 
the vaccine, were in the GIT the DC interacts and the inductive signals from the surrounding 
microenvironment (Manicassamy & Pulendran 2011).  
DCs are a heterogeneous, complex and multifunctional group of APCs, and they play a critical 
role in the activation of naive T-cells. Targeting DC is strategically to induce an antigen-specific 
immunity (Tyler et al. 2013), and have been obtained using a 12-mer DC peptide 
(Mohamadzadeh et al. 2009; Mohamadzadeh et al. 2010; Tyler et al. 2013). In a previous study, 
Mohamadzadeh (2009) revealed the increased survival rate by 75 % in mice challenged with 
Bacillus anthracis (see section 1.3.1), after oral treatment using antigens fused to DC-targeting 
peptide.  
 
1.8 The outline of this study 
The aim of this study was to contribute to the tuberculosis (TB) vaccine development, by 
developing methods for anchoring vaccine candidates to the peptidoglycan layer in gram positive 
bacteria using Lysine Motif (LysM) domains. In a previous study by Øverland (2013), it was 
shown that lactobacillus producing the Ag85B-ESAT6 antigen with a DC-targeting sequence 
fused to the C-terminus, anchored N-terminally to the bacterial surface gave promising responses. 
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Attachment of LysM domains to this antigen-containing protein would open up the opportunity to 
produce the protein in E. coli, purify it, and then anchor it to the peptidoglycan layer of the 
bacteria used as delivery vehicle, as for example lactic acid bacteria (LAB). The resulting LAB 
charged with antigen-containing proteins would then not be a GMO. Several LysM-containing 
fusion proteins were generated and their anchoring to various bacteria was studied. 
Two anchors were tested in this study, the single LysM domain from the protein Lp_3014, and 
the double LysM domain from the protein Lp_2162, both naturally found in the secreted proteins 
from L. plantarum. Lactobacillus strains and B. subtilis are both capable of resisting the low pH 
in the stomach and the high bile concentrations in the intestine (Marteau et al. 1997) and both 
were therefore tested. In total, four species were assessed as carriers; L. rhamnosus GG, L. 
gasseri, L. plantarum (WCFS1) and B. subtilis. 
The idea was to orally administrate the resulting antigen-charged strains, which would increase 
the need for the displayed protein to resist degradation during passage through the rough 
environments in the digestive tract (Wells 2010; Wells & Mercenier 2008). Therefore, the effects 
of environmental factors such as pH and bile, on the stability of the displayed antigens were 
tested in this study.   
In summary, the following four experimental steps were carried out: 
1. One or two LysM domains were attached N-terminally to the Ag85B-ESAT6-DC fusion 
protein (Øverland 2013), resulting in the two final fusion proteins; 3014_Ag85B-ESAT6-
DC (called 3014-TB) and 2162_ Ag85B-ESAT6-DC (2162-TB). Both fusion proteins 
included a (His)7-tag attached to the N-terminus of 3014 and 2162. Gene fragments 
encoding these fusion proteins were cloned into E. coli plasmids (pBAD) to produce the 
proteins in large quantities. 
2. The possibility for E. coli strains to express 3014-TB and 2162-TB were evaluated. 
Following intracellular production, attempts were made to purify the proteins from cell 
extract using the His-tag t the N-terminus. 
3. The final fusion proteins were further anchored to the cell surfaces of Lactobacillus and B. 
subtilis, using the N-terminal attached LysM domains. Following the display of 3014-TB 
and 2162-TB on the bacterial cells, the displayed proteins were visually semi-quantified 
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using flow cytometry and western blots. Following the semi-quantification, the two fusion 
proteins displayed at the cell surface were compared.  
4. The stability of the cells charged with either 3014-TB or 2162-TB, and the LysM domain 
binding strength were tested by subjecting the bacteria to conditions resembling those in the 
digestive tract, namely low pH and the presence of bile. Storage stability was also assessed. 
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2. MATERIALS 
 
2.1 Laboratory consumables  
Laboratory consumables      Supplier 
Centrifugal device (10K WCO)     Pall 
CL-Xposure
TM
 Film       Thermo 
Scientific 
Cuvettes 
Disposable cuvettes, 1.5 ml      Brand 
Eppendorf tubes       Axygen 
Regular 1.5 m 
Sequencing tubes 
FastPrep® tubes and lids                   Fisher Scientific 
Nunc tubes, 15 ml and 50 ml      Nunc 
Sterile filters, 0.22 µn pore size     Millex GP 
Syringes, 10ml - 50 ml      Plastipak 
Ultracel® 10 K                  Amicon® Ultra 
Various glass equipment      Labsystems 
Waterbaths 
 
Instruments        Supplier 
Authorized Thermal cycler      Eppendorf 
Bench top UV Transilluminator     UVP 
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BioLogic LP        Bio-Rad 
iBLOT™         Invitrogen 
Centrifuges: 
Eppendorf centrifuge, 5415 R     Eppendorf 
Eppendorf centrifuge, 5430 R             Eppendorf 
Table centrifuge        Biofuge Pico, Heraeus 
Vacuum centrifuge                             Maxi Dry Lyo, Heraeus 
Avanti™ centrifuge J-25                             Beckman Coulter 
Electrophoresis electricity supplier  
Gene Pulser II        Biorad 
Photo equipment: 
Gel Doc machine       Bio-Rad 
Qubit ™ Fluorometer      Invitrogen 
PowerPak 300       Bio-Rad 
SNAP i.d. Protein detector system     Millipore 
Steri-Cycle CO2 Incubator     Thermo-electron Corporation 
 
2.2  Software 
Software         Supplier 
MacsQuantify™Software      Miltenyi Biotec  
pDRAW32        www.acaclone.com 
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2.3  Chemicals   
Chemicals        Supplier 
Acetone, C3H6O        Merck 
Agar         Merck 
Agarose 
SeaKern® LE agarose      Lonza 
Nusieve® GTG® agarose       Lonza 
Ampicillin        Merck 
Arabinose, C5H10O5       Sigma-Aldrich 
Calsium chloride, CaCl2      Merck 
Chloroform, CHCl3       Merck 
Disodium hydrogen phosphate, Na2HPO4    Merck 
DTT (DL- Dithiothreito)      Sigma 
EDTA, C10H16N2O8       Merck 
Erythromycin, C37H16N2O8       Merck 
Ethanol, C2H5OH       Sigma-Aldrich 
Ethidium Bromide, EtBr      Biotech 
Fructose, C6H12O6       Sigma-Aldrich 
L-arabinose        Sigma-Aldrich 
L-arginine        Sigma 
Glucose, C6H12O6       Merck 
Glycerol, C3H8O3       Merck 
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Glycine, C2H5NO2        Duchefa Biochemie  
Guanidium HCl       Sigma-Aldrich 
Isopropyl β-D-1-thiogalactopyranoside (IPTG)   Sigma 
Magnesium chloride, MgCl       Aldrich 
Magnesium sulfate, MgSO4      Sigma 
Ni-NTA His-Bind® Superflow     Qiagen 
Oxidized Glutathion        Sigma 
Phenylmethanesulfonyl fluoride (PMSF) 
PolyEthylenGlycol, 1500 (PEG1500)    Merck-Schuchardt 
Potassium chloride, KCl      Merck 
Potassium dihydrogen phosphate, KH2PO4    Merck 
Sodium chloride, NaCl      Merck 
Sodium hydroxide, NaOH      Merck 
Reduced Glutathion       Sigma 
Trichloroacetic acid (TCA), C2HCl3O2    Sigma 
Tris-base, C4H11NO3      Sigma  
Tris-HCl, C4H11NO3 x HCl      Sigma 
Tween20        Sigma-Aldrich 
Β-mercaptoetanol       Sigma-Aldrich 
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2.4 Proteins, enzymes and related standard solutions 
Protein/enzymes        Supplier 
5X In-Fusion HD Enzyme Premix      Clontech 
Antibodies 
 Penta - His™ Antibody, BSA free      Quagen 
 HRP-Rabbit Anti-Mouse IgG     Daco 
 ESAT6 Mouse mcAb (ab26246)     Abcam 
Bovine serum Albumin (BSA)      Sigma 
Lysozyme          Sigma 
Protein standards 
      BenchMark™ Protein Ladder       Invitrogen 
      MagicMark™        Invitrogen 
Phusion High Fidelity DNA polymerase     Finnzymes 
Q5™ High-Fidelity 2x Master Mix      NEB 
Restriction buffer 
      NEbuffer 3        NEB  
      NEbuffer 4         NEB 
Restriction enzymes 
      BglII         NEB 
      EcoRI         NEB  
      HindIII         NEB 
      NdeI         NEB 
      SalI         NEB  
T4 DNA ligase        NEB 
VWR RED Taq DNA polymerase Master Mix     Finnzymes 
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2.5 Nucleotodes and DNA 
DNA          Supplier 
dNTP-mix, 10mM        NEB 
DNA standard 
GeneRuler™ 1kb DNA Ladder         Fermentas 
 
 
2.6 Primers  
The primers used in this study are shown in Table 2.1 and 2.2. The primers sequences are shown 
in Table 2.1 while the primers are described in Table 2.2. 
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Table: 2.1. Primer sequences. The red colour indicates restrictions sites. The use of these 
primers is summarized in Table 2.2.  
Name Sequence  Restriction site 
in sequence 
3014AG85R CCTGGACGACTAAAGTCGACAGTTGAACTCGT
TGAAGTGGT 
SalI 
3014 F GGAGTATGATTCATATGAAAAAACTTGTAAGT
ACAATCGTAACTAC 
NdeI 
3014HisF TCATCATCACAGATCTGACTCAACTTACACCG
TTAAGAGC 
BglII 
3014 R GACGACTAAAGTCGACAAGGGCCCAAGCAGC
C 
SalI 
Ag85DCHisR GCCAAGCTTCGATTCTTATGGCCGTTGTGGCG
T 
HindIII 
Ag85Fus3014F CAACGAGTTCAACTGTCGACTTTAGTCGTCCA
GGTT 
SalI 
Lp_3014AGF TTGGGCCCTTGTCGACTTTAGTCGTCCAGGTTT
GCC  
SalI 
Lp_2162_MSP_
F 
GGAGTATGATTCATATGTCACAAGCACATACA
AC 
NdeI 
Lp_2162_SVAG
_R 
CCGGGGTACCGAATTCTTATGGCCGTTGTGGC
G 
EcoRI 
P2162LS_R GACGACTAAAGTCGACGCCGGTTACAGAACC
AGT 
SalI 
P2162_SV_R CTGGACGACTAAAGTCGACACCTGTTTTTTGA
CT 
SalI 
P2162_USP_F CATCATCATCATCACGCTGCTGCTGCTAGATC
TGCCTCAATCACTGTAAAAGC  
BglII 
SeqAg85F GCCGGTAGTTCAGCGAT  
Seq852F CCGCGGGTGGTCATAAT  
 
 
 
Table 2.2. Description of the application of the various primers. See Table 2.1 for primer 
sequences 
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Name Description 
3014AG85R Reverse primer, for the amplification of the gene fragment encoding the 
LysM domain, which is part of the p_3014 (pBAD-derivative).  
3014F Forward primer, for the amplification of the gene fragment encoding the 
LysM domain, which is part of the Lp_3014 (pSIP-derivative).  
3014HisF Forward primer, for the amplification of the gene fragment encoding the 
LysM domain, which is part of the p_3014 (pBAD-derivative). 
3014R Reverse primer, for the amplification of the gene fragment encoding 
LysM domain, which is part of the Lp_3014 (pSIP-derivative). 
Ag85DCHisR Reverse primer, for the amplification of the gene fragment encoding the 
Ag85-ESAT6-DC antigen in pBAD-derivatives. 
Ag85Fus3014 F Forward primer, for the sequencing the fusion between the gene fragment 
of LysM domain (3014) and Ag86B-ESAT6.  
Lp_3014AGF Forward primer, for the amplification of the gene fragment encoding 
Lp_3014_Ag85B-ESAT6-DC (pSIP-derivatives). 
Lp_2162_MSP_F Forward primer, for the amplification of the gene fragment encoding 
Lp_2162 (pSIP-derivatives).  
Lp_2162_SVAG_R Reverse primer, for the amplification of the gene fragment encoding 
Ag85B-ESAT6-DC (pSIP-derivatives). 
P2162LS_R Reverse primer, for the amplification of the gene fragment encoding 
p_2162_L (pBAD-derivatives).  
P2162_SV_R Reverse primer, for the amplification the gene fragment encoding p_2162 
(pBAD-derivatives). 
P2162_USP_F Forward primer, for the amplification the gene fragment encoding 
p_2162_S (pBAD-derivatives). 
SeqAg85F Forward primer, for the internal sequencing of the gene fragment Ag85B-
ESAT6, reaching the pBAD vector. 
Seq852F Forward primer, for the sequencing of the pBAD vector, downstream of 
the inserted gene fragment encoding the protein 3014-TB 
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2.7 Bacterial and plasmids 
Tables 2.3 and 2.4 list the bacterial strains and plasmids used in this study, respectively. 
Table 2.3. Bacterial strains.  
Strain Source 
Escherichia coli Top10 cells Invitrogen 
Lactobacillus plantarum WCFS1 (Kleerebezem et al. 2003) 
Bacillus subtilis WB800N MoBiTech, Germany 
Lactobacillus brevis  SMZ20556 ATCC 
Lactobacillus curvatus DSMZ 
L. rhamnosus GG ATCC 53103 
Lactobacillus acidophilus ATCC 
Lactococcus lactis subs. Lactis (Park et al. 2013) 
Pediococcus acidolactis LMGT2351 LMGT * 
Carnobacterium pisicola UI49 LMGT 2332 LMGT * 
Pediococcus pentosaceus LMGT 2001 LMGT 
L.gasseri ATCC33323T (Azcarate-Peril et al. 2008) 
Enterococcus faecium LMGT 2749 LMGT * 
L. sakei Lb790 (Sørvig et al. 2003) 
*Strains collected at LMGT, Laboratory of Microbial Gene Technology. Dep. Chemistry, 
Biotechnology and Food Science, NMBU. 
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Table 2.4 Plasmids 
Plasmids Description Source  
Lp_2162_SMSP pSIP-derivative, for the production of 2162-
TB_S in L. plantarum WCFS1. 
This work 
Lp_2162_LMSP pSIP-derivative, for the production of 2162-
TB_L in L. plantarum WCFS1. 
This work 
Lp_3014_Ag85B_ESAT6-
DC 
pSIP-derivative, for the production of 3014-
TB in L. plantarum WCFS1. 
This work 
pBAD_2162_SUSP pBAD-derivative, for the production of 
2162-TB_S in E. coli. 
This work 
pBAD_2162_LUSP pBAD-derivative, for the production of 
2162-TB_L in E. coli. 
This work 
p_3014Gagp24 pSIP-derivative, for the retrieval of the gene 
encoding 3014.  
(Urdal 2013) 
p_1261_Ag65B-E6 pSIP-derivative, for the retrieval of the 
Ag85B-ESAT6-DC gene fragment. 
(Øverland 
2013) 
pBAD Empty vector (pBAD-derivative not 
harboring any target-gene) 
Invitrogen 
pBAD3014_Ag85B_ESAT6- 
DC 
pBAD-derivative, for the production of 
3014-TB in E. coli 
This work 
pBAD_Ag85B_ESAT6 pBAD-derivative, for the production of 
Ag85B-ESAT6 in E. coli 
This work 
pBAD_3014_Ag85B_ESAT6 pBAD-derivative, for the production of 
3014_Ag85B-ESAT6, without the DC-
peptide in E. coli 
This work 
pBAD_2162_Ag85B_ESAT6 pBAD-derivative, for the production of 
2162_Ag85B-ESAT6, without the DC-
peptide, in E. coli 
This work 
pBAD_Elu pBAD-derivative, not harboring the gene 
fragment encoding 3014-TB or 2162-TB 
G. Mathiesen  
Unpublished 
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2.8 Kits  
Kits          Supplier  
iBlot™ Dry Blotting system       Invitrogen 
 Blotting roller  
iBlot™ Gel Transfer Stack, Mini and Regular 
 iBlot™ Cathode stack, top 
 iBlot™ Anode stack, bottom 
 iBlot™ Disposable sponge  
 iBlot™ Filter paper 
 iBlot™ Gel Transfer Device 
Mini Trans - Blot® Electrophoretic Transfer Cell    Bio - Rad 
 2 gel holder cassettes 
 4 fiber pads 
 Modular electrode assembly 
 Blue cloning unit 
 Lower buffer chamber 
 Lid with cables 
NucleoSpin® Plasmid Miniprep Kit      Macherey-Nagel 
NucleoSpin® Plasmid Coloumns 
Collection tubes, 2ml 
Resuspension Buffer A1 
Lysis Buffer A2 
Wash Buffer AW 
Wash Buffer A4 
Elution Buffer AE 
Rnase A 
NucleoSpin® Extract II       Macherey-Nagel 
NucleoSpin® Extract II Coloumn 
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Collection tubes, 2 ml 
Binding Buffer NT 
Wash Buffer NT3 
Elution Buffer NE 
Novex® NuPAGE® SDS-PAGE Gel Systems     Invitrogen 
 NuPAGE®Bis-Tris Gels 10 % 8 cm x 8 cm x 1mm, 10 wells 
 NuPAGE® LDS Sample Buffer (4x) 
 NuPAGE® Reducing agent (10x) 
 NuPAGE® Mops Running Buffer  
Pellet Paint® Co-Precipitant        Merck 
3 M sodium acetate, pH 5.2 
QIAamp® DNA Mini Kit        Qiagen 
Collection tubes (2ml)  
QIAamp® ATL Buffer  
QIAamp® Elution Buffer (AE)  
QIAamp® Lysis Buffer (AL)  
QIAamp® Mini Spin Column  
QIAamp® Proteinase K solution  
QIAamp® Wash Buffer 1 (AW1) 
QIAamp® Wash Buffer 2 (AW2) 
Qubit® dsDNA BR Assay Kit      Invitrogen 
Qubit™ Assay tubes 
Qubit™ dsDNA BR buffer 
Qubit™ dsDNA BR reagent 
Qubit™ dsDNA BR standard 1 and 2 
Qubit™ fluorometer 
SNAP i.d.® Protein detection system     Millipore 
SNAP i.d. Single Well Blotter 
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SNAP i.d. Spacer 
SNAP i.d. Blot Roller 
Supersignal® West Pico Chemiluminiscent Substrate    Thermo Scientific  
Luminol/Enhancer Solution 
Stable Peroxide Solution 
 
2.9 Mediums and agars 
Mediums       Suppliers 
2 X TY medium 
16 g Bacto™ Tryptone     BD (Becton, Dickinson and Company) 
10 g Bacto™ yeast extract     BD (Becton, Dickinson and Company) 
5 g NaCl 
dH2O to 1 liters  
autoclaved 121⁰C for 15 min 
 
BHI (Brain-Heart-Infusion) medium   Oxoid 
37g BHI 
dH2O to 1 liters 
Sterilized in autoclave for 15 minutes at 115⁰C    
 
HS medium 
10 ml 10 x Spizizen’s salt 
2.5 ml 20 % (w/v) glucose 
5 ml 0.1 % (w/v) L - tryptophan 
1 ml 2 % (w/v) casein 
5 ml 10 % (w/v) yeast extract (Difco) 
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10 ml 8 % (w/v) arginine, 0.4 % histidine 
66.5 ml dH2O 
All components were autoclaved separately, and the tryptophan solution was sterile 
filtrated  
 
LB medium  
10 g Bacto™ Tryptone     BD (Becton, Dickinson and Company) 
5 g Bacto™ yeast extract     BD (Becton, Dickinson and Company) 
10 g NaCl 
dH2O to 1 liter  
autoclaved for 15 minutes at 115⁰C  
 
LS medium 
10 ml 10 x Spizizen’s salt 
2.5 ml 20 % (w/v) glucose 
0.5 ml 0.1 % (w/v) L - tryptophan 
0.5 ml 2 % (w/v) casein 
5 ml 2 % (w/v) yeast extract (Difco) 
0.25 ml 1M MgCL2  
0.05 ml 1M CaCl2 
80 ml dH2O  
All components were autoclaved separately, and the tryptophan solution was sterile 
filtrated 
 
MRS (de Man, Rogosa, Sharpe) medium    Oxoid 
 52 g MRS 
 dH2O to 1 Liter  
 Sterilized in autoclave for 15 minutes at 115 ⁰C 
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MRSSM medium 
5.2 g MRS 
 17.1 g Sucrose (500 mM)  
 2.0 g MgCl2 x 6 H2O (100 mM) 
dH2= to 100 ml, and sterile filtrated using 0.2 µm pore size 
 
S.O.C medium 
2 g Bacto™ Tryptone    BD (Becton, Dickinson and Company) 
0.5 g Bacto™ yeast extract    BD (Becton, Dickinson and Company) 
0.057 g NaCl 
0.019 g KCl 
0.247 g MgSO4 
60 ml dH2O 
Sterilized in autoclave for 15 min at 115⁰C  
After cooling down to room temperature, 1 ml 2 M glucose (sterile filtered, with pore size 
0.2 µl) was added and sterile dH2O was added to 100 ml 
 
Appropriate antibiotics were added to both liquid media and plates, as described in section 3.1.  
 
2.10 Buffers and solutions 
Buffers/ Solutions       Content 
 
0.5 M EDTA        186.1 g EDTA-Na2 
         1 L dH2O 
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1x PBS (Phosphate Buffered Saline), pH 7.4   8 g/l NaCl 
         0.2 g/l KCl 
         1.44 g/l Na2PO4 
         0.24 g/l KH2PO4 
         dH2O to 1L 
 
0.1 M NaPO4 (Sodium Phosphate buffer), pH 7.4   3.1 g NaH2PO4 * H2O 
         10.9 g Na2HPO4 
         dH2O to 1L 
 
50x TAE        242 g Tris Base  
                   57.1 ml acetic acid  
                              100 ml 0.5 EDTA, pH 8 
         dH2O to 1L 
 
 
1x TBS (Tris Buffered Saline), pH 7.4    150 mM NaCl  
                                   25 mM Tris HCl, pH 7.4 
         dH2O to 1L 
 
TTBS         TBS 
                     0.05 % (v/v) Tween 20 
 
1 M Tris HCl                 121.1 g Tris Base  
         42 ml HCl   
             dH2O to 1L
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3. METHODS 
 
3.1 Growth of bacteria cultures 
Bacterial cultures were grown in appropriate liquid mediums or agar plates. To select for bacteria 
containing plasmids with antibiotic resistance, the appropriate antibiotic was added.  
Escherichia coli cultures were grown in either LB or BHI media. Liquid cultures were incubated 
at 37⁰C and shaking at 200 rpm, while agar plates were incubated at 37⁰C whiteout shaking. 
Bacteria containing derivatives of pBAD-plasmids were selected for using the final concentration 
of 200 µg/ml ampicillin. Bacteria containing derivatives of pSIP-plasmids were selected for using 
the final concentration of 200 µg/ml erythromycin. 
Bacillus subtilis were grown in liquid 2xTY medium at 37⁰C and shaking at 200 rpm, while 
2xTY agar plates in 37⁰C without shaking.  
Lactobacillus spp were grown in liquid MRS mediums or MRS agar plates at 37⁰C, without 
shaking. Bacteria containing pSIP-plasmids derivatives were selected for using the final 
concentration of 10 µg/ml erythromycin. 
 
3.2 Long term storage of bacteria 
Bacterial cultures were long-time stored in 20% (v/v) glycerol at –80⁰C, to prevent cells from 
disruption at low temperatures.  
Materials:  
87% (v/v) glycerol 
1.5 cryovial  
Bacteria culture 
Medium (BHI, LB, 2xTY and MRS)  
 
Procedure:  
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Bacterial cultures were grown using appropriate media and conditions, overnight. 1ml culture 
was mixed with 300 µl 87% (v/v) sterile glycerol in a 1.5 ml cryvial, and mixing, the vial was 
stored at –80⁰C 
Stored glycerol stocks were used to start cultures by using toothpicks to scrape off some ice, 
which was transferred to tubes containing appropriate media and antibiotics.  
 
3.3 Isolating plasmids from bacteria cultures 
Bacterial cultured plasmids were isolated with the NucleoSpin® Plasmid miniprep Kit. 
Materials: 
NucleoSpin® Plasmid miniprep Kit, Macherey-Nagel (see materials, section 2.8).  
 
Procedure:  
The manufactured protocol from the supplier was followed for plasmids isolations.  
1. 1–5 ml of an overnight bacterial culture was centrifuged at 11,000 x g for 30 sec in standard 
eppendorftubes, before the supernatant was discarded.  
2. The cell pellet was re-suspended in 250 µl Suspension Buffer (A1). 
3. After adding 250 µl Lysis Buffer (A2), the tube was inverted 6–8 times and incubated at 
room temperature for 5 min, or to the lysate appeared clear. 
4. After adding 300 µl Neutralization Buffer (A3), the tube was inverted 6–8 times, and 
centrifuged at 11,000 x g for 5 min at 24⁰C, to pellet the precipitate. 
5. A NucleoSpin® Plasmid column was placed in a collection tube and the supernatant to the 
column. The column was centrifuged at 11,000 x g for 1 min, and the flow-through was 
discarded. The column was replaced into the collection tube.  
6. 600 µl Wash Buffer (A4) was added to the column and then centrifuged at 11,000 x g for 1 
min. The flow-through was discarded and the column replaced into the empty collection 
tube. 
7. The collection tube was centrifuged at 11,000 x g for 2 min to remove remaining ethanol, 
before the collection tube was discarded. 
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8. The column was placed into a clean Eppendorf tube, and 50 µl Elution Buffer (AE) was 
added before incubated at room temperature for 1 min and centrifuged at 11,000 x g for 1 
min. 
9. The eluted DNA was stored at –20⁰C 
 
3.4 Genomic DNA isolation 
Genomic DNA from Lactobacillus plantarum was isolated using QIAamp® DNA Mini Kit. 
 
Material: 
QIAamp® DNA Mini Kit, Qiagen (see material, section 2.8) 
 
Procedure: 
1. 1–5 ml of an overnight bacterial culture was centrifuged at 7500 rpm for 10 min in standard 
eppendorftubes before the supernatant was discarded.  
2. The cell pellet was then re-suspended in 180 µl ATL buffer. 
3. 200 µl proteinase K was added to the mixture and vortexed for 15 sec, before incubating 
the mixture at 56⁰C to lyse completely. 
4. The tube was centrifuged briefly to remove drops from the lids inside.  
5. To retrieve DNA free from RNA, 4 µl RNase (100mg/ml) was added before vortexed 15 
sec and incubated at room temperature for 2 min. Drops from the inside of the lid were 
removed by briefly centrifugation.  
6. After adding 200 µl Buffer AL and vortexing for 15 sec, the reaction mixture was 
incubated for 10 min at 70⁰C. 
7. 200 µl 96% (v/v) ethanol was added and the sample was vortexed for 15 sec. 
8. After adding the sample to a QIAamp® Mini Spin Column in 2 ml collection tubes, the 
samples were centrifuged at 8000 rpm for 1 min. The QIAamp® Mini Spin Column was 
then replaced in a new clean collection column, and the collection tube containing the 
filtrate was discarded.  
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9. 500 µl Wash buffer (AW1) was added and the collection tube was centrifuged at 8000 rpm 
for 1 min. The collection tube was discarded and the QIAamp® Mini Spin Column was 
replaced in a new clean collection tube. 
10. After adding 500 µl Wash buffer (AW2), the collection tube was centrifuged at 8000 rpm 
for 3 min. The collection tube was discarded and the QIAamp® Mini Spin Column was 
replaced in a new clean collection tube. 
11. Potential buffer AW2 carryover was removed by centrifugation at 13, 000 rpm for 1 min. 
12. The QIAamp® Mini Spin Column was placed in a clean 1.5 ml eppendorftube, and the 
collection tube containing the filtrate was discarded.  
13. After adding 200 µl Elution buffer (AE) to the column, the tube was incubated at room 
temperature for 5 min. The sample was centrifuged at 8000 rpm for 1 min. 
14. The eluate was saved and the QIAamp® Mini Spin Column was replaced in a new 1.5 ml 
eppendorftube. The column was added 200 µl Elution buffer (AE), incubated at room 
temperature for 5 min and centrifuged at 8000 rpm for 1 min. 
15. The eluate from step 13 was mixed with the eluate from step 14, and used directly. 
 
3.5 The polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) is a biochemical method that relies on thermo-cycling and 
a thermostable polymerase to amplify specific DNA fragments. PCR is divided into three steps, 
denaturation, annealing and extension. In the first step, double-stranded DNA (dsDNA) is 
denatured by heating, which causes separation into two single-stranded DNA (ssDNA) threads. 
These ssDNA threads acts as templates for subsequent polymerase-catalyzed DNA synthesis. 
Two oligonucleotides are then annealed to the ssDNA sequences when the temperature is 
lowered, functioning as primers for the thermostable polymerases, which subsequently 
incorporate deoxynucleotides (dNTPs), synthesizing the DNA strands. In the thermal cycling 
device, these three steps are repeated, to give a high amount of the specific DNA fragment.   
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3.5.1  PCR reactions with Q5™ High-Fidelity DNA Polymerase 
Materials 
Primers (see material, section 2.6)  
Q5™ High-Fidelity DNA Polymerase Master Mix 
 
Procedure: 
1. Reactions were set up according to the protocol from the supplier of the Q5™ High-
Fidelity DNA Polymerase. Reactants were mixed in clean PCR tubes according to Table 
3.1. During preparation of the reaction mixtures, the tubes kept on ice at all times.  
 Table 3.1 Q5 High-Fidelity PCR reactants 
Reactants volumes (µl) Final 
Concentrations 
5X Q5 Reaction Buffer 10  1 X 
10 mM dNTP 1 200 µM 
Forward primer 1 0.1–10 µM 
Reversed primer 1 0.1–10 µM 
Template DNA Variable <1.000 ng/50 µl 
Q5 High-Fidelity DNA Polymerase 0.5 0.02 U/µl 
dH2O To 50   
 
2. The tubes were placed in the thermal cycler, and the program was set according to Table 
3.2. 
Table 3.2 Q5 High-Fidelity cycling program 
Program Temperature (⁰C) Time Cycles 
Initial denaturation 98 30 sec 1 
Denaturation 98 10 sec 25 
Annealing 50 - 72 * 30 sec 25 
Elongating  72 20- 30 sec/kb 25 
Final elongating 72 2 min 1 
* The annealing temperature was adapted to the melting temperature of the primers used in the 
reactions. The melting temperature of the primers was calculated using the TM-calculator, and 
the annealing temperatures used were lower than the calculated melting temperature.  
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3.5.2 PCR with the VWR® Taq DNA Polymerase Master Mix 
PCR with the VWR Taq DNA polymerase Master Mix was used to identify correct plasmids by 
colony PCR. The VWR Taq DNA polymerase Master Mix contains an inert red dye and 
stabilizer, so that the PCR product can be applied directly to the gel without the need of a loading 
dye.  
Materials: 
Primers (see material, section 2.6)  
Taq Master Mix RED 
 
Procedure: 
1. Reactions were set up according to the protocol from the supplier of the VWR® Taq 
DNA polymerase Master Mix. Reactants were mixed in clean PCR tubes according to 
Table 3.3. During preparation of the reaction mixtures, the tubes were kept on ice at all 
times. 
 Table 3.3 Red Taq PCR reactants 
 
 
 
 
2. The tubes were placed in the thermal cycler, and the program was set according to table 
3.4. 
Table 3.4 Red Taq cycling program 
Program Temperature 
(⁰C) 
Time (minutes) Cycles 
Initial denaturation 94 3 1 
Denaturation 94 1 30 
Annealing 55* 2 30 
Elongating  72 3 30 
Final elongating 72 10 1 
Reactants volumes (µl) Final Concentrations 
2.0 X Taq Master Mix 25  1 X 
Forward primer 1 0.1–10 µM 
Reversed primer 1 0.1–10 µM 
dH2O 23  
Template DNA Variable Variable 
METHODS 
38 
 
* The annealing temperature was adapted to the melting temperature of the primers used in the 
reactions. The melting temperature of the primers was calculated using the TM-calculator, and 
the annealing temperatures used were lower than the melting temperature.  
 
 
3.6 Agarose Gel Electrophoresis 
DNA fragments can be separated according to size using agarose gel electrophoresis. An electric 
charge over the gel causes the negatively charged DNA fragments to migrate towards the positive 
pole. The smaller fragments meet less resistance from the gel pores and therefore migrate faster, 
separating them from the slower migrating larger fragments. Ethidium bromide was added to the 
agarose gel, in order to visualize the fragments after UV light exposure, and a DNA ladder was 
used to determine the size of DNA fragments. 
Materials:  
1x TAE buffer  
10 mg/ml Ethidium Bromide  
SeaKem® LE Agarose 
DNA ladder  
Loading dye 
Procedure: 
1. For preparing a 1.2 % Agarose gel, 12 g SeaKem® LE Agaros was dissolved in 1 L 1x 
TAE. The solution was autoclaved at 115⁰C for 15 min and stored at 60⁰C. 
2. The gels were made by mixing 60 ml solution and 1 µl 10mg/ml ethidium bromide, and 
then poured into a moulding tray with well combs. 
3. After approximate 20 min the combs were removed, and the now harden gel was 
transferred to electrophoresis chambers and covered with 1x TAE buffer. 
4. 0.1 volume dye was added to each sample before loaded onto the gel, using an appropriate 
DNA ladder. The gel was run at 90 V for 15–40 min.  
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3.7 DNA purification and extraction from agarose gels 
DNA was extracted from agarose gels using the NucleoSpin® Extract II Kit following the 
provided protocol for extraction and purification.   
Materials:  
NucleoSpin® Extract II Kit, Macherey-Nagel (see materials, section 2.8) 
Procedure:  
1. 200 µl Binding buffer (NT) was added to each 100 mg agarose gel. The sample was 
incubated for 5–10 min at 50⁰C and vortexed every 2–3 min, until the gels were 
completely dissolved.  
2. After placing the NucleoSpin® Extract II column into the collection tube, the sample was 
loaded and centrifuged at 11,000 x g for 1 min. The flow-through was discarded and the 
column replaced into the collection tube. 
3. 700 µl Wash buffer (NT3) was added and the sample was centrifuged at 11,000 x g for 1 
min. The flow-through was discarded and the column replaced into the collection tube.  
4. The Wash buffer (NT3) was completely removed using centrifugation at 11,000 x g for 2 
min. 
5. After placing the columns into clean eppendorftubes, the DNA yield was increased with 
the addition of 15–50 µl Elution buffer (NTE) and incubation for 1 min. The sample was 
centrifuged at 11, 000 x g for 1 min. 
6. The eluted DNA was stored at –20⁰C. 
 
3.8   Restriction enzyme digestion of DNA 
Restriction enzyme digestion is a method used to digest double-stranded DNA at specific 
sequences, called restriction sites. Restriction enzymes can break the DNA chains in several 
ways, one resulting in the formation of blunt ends, while the other results in the formation of 
sticky ends. The blunt end is formed by cutting at the exact same location in both DNA strands, 
while sticky ends are formed by cutting at different locations, which causes an overhang of bases.  
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Materials:  
10 x BSA (if needed)  
10 x restriction buffers (see material, section 2.4)  
DNA to be cut  
Restriction enzymes (see material, section 2.4) 
 
Procedure: 
1. Reactants were mixed according to Table 3.5 in Eppendorf tubes.  
Table 3.5 Restriction mixtures for restriction enzymes 
Reactants  Volumes 
(µl) 
Template 15–25 
Restriction enzymes 2 
NE Buffers 5 
BSA 5 
dH2O To 50  
 
2. After incubation for 2 hours at 37⁰C, the samples were run on agarose gels, separating the 
fragments according to their sizes. 
 
3.9 Determination of DNA concentration 
The DNA concentration of plasmids and PCR fragments after purification were determined using 
the Qubit® dsDNA BR Assay Kit. 
Materials: 
Qubit® dsDNA BR Assay Kit (see material, section 2.8)  
Qubit™ fluorometer 
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Procedure: 
1. The Qubit™ Reagent was diluted with Qubit™ Buffer by a factor of 1:200 in a 200 µl 
stock solution.  
2. Two Qubit™ standards of 10 µl were each mixed with the 190 µl stock solution. The 
mixture was vortexed and incubated at room temperature for 2 min.  
3. 1 µl of each sample were mixed with 199 µl stock solution, using vortex and incubation at 
room temperature for 2 min.  
4. The the Qubit™ Fluorometer was equilibrated using prepared standards. The DNA 
concentration in each sample was determined. 
5. The samples were chilled on ice and stored at –20⁰C. 
 
3.10  Ligation of DNA fragments 
DNA fragments can be ligated by DNA ligases. In this study Quick T4 DNA ligase was used. 
This ligase can join both blunt and sticky ends of DNA fragments through the formation of a 
phosphodiester bond between the 5’ phosphate- and 3’ hydroxyl-ends of the DNA fragments. The 
ligation buffer supplies ATP and Mg
2+ 
to the solution, which is needed for the ligase to be active. 
Materials: 
2x Quick Ligation Reaction Buffer  
DNA to be ligated (fragment and insert)  
Quick T4 DNA Ligase 
 
Procedure: 
1. 50 ng vector was mixed with 3x ng of the insert in PCR tubes. The total volume was 
adjusted to 10µl. 
2. 10 µl 2x Quick Ligation Reaction Buffer were added to the solution. 
3. 1 µl Quick T4 DNA Ligase was added to the solution and incubated at room temperature 
for 5 min. 
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3.11  Preparation of competent bacterial cells 
Competent bacterial cells can take up plasmids from the extracellular environment, resulting in 
genetically modified bacteria. Transformation, i.e. uptake of DNA, is usually achieved by 
applying an electric pulse or a heat shock. Bacterial cells become (or can be made) competent in 
the exponential phase, and is therefore harvested in this phase  
 
3.11.1  Preparation of electro-competent Lactobacillus plantarum WCFS1 
Electro-competent L. plantarum were made by growing them in a medium containing high 
amounts of glycine. The glycine is incorporated into the cell wall, replacing L-alanine, leaving 
the cell wall more permeable and favoring plasmid uptake. The procedure was done according to 
the protocol described by Aukrust et al. (1995). 
Materials:  
20% glycine (w/v)  
1 mM MgCl2 
2x MRS medium 
MRS medium 
PEG 1500 
TEN buffer 
 
Procedure: 
1. 10 ml MRS containing L. plantarum cultures were incubated in 30⁰C overnight, and used 
to create dilution series.  
2. In 12 tubes with 10 ml MRS; 1 ml overnight culture was transferred to the first tube, and 
mixed well. Then 1 ml was transferred further to the next tube, and so on. These tubes 
were incubated in 30⁰C. 
3. The samples that reached OD600 = 0.5–0.7 were used further to make electro-competent 
cells. 
4. After transferring the sample to a 50 ml Nunc tube containing; 20 ml 2xMRS, 5 ml 20% 
glycine and 5 - 10 ml dH2O (Total volume 40 ml), the sample was incubated in 30⁰C until 
OD600 = 0.7 was reached. 
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5. The cells were cooled down with ice before centrifuged at 5200 rpm for 5 min at 4⁰C. 
After discarding the supernatant, the pellet was washed with 10 ml TEN buffer and 
centrifuged at 5200 rpm for 5 min at 4⁰C. 
6. The supernatant was discarded and the pellet washed using 40 ml 1 mM MgCl2. The 
solution was centrifuged at 5200 rpm for 5 min. 
7. The supernatant was discarded and the pellet washed using 5 ml 30 % PEG. The solution 
was centrifuged at 6000 rpm for 10 min at 4⁰C. 
8. The cells were re-suspended in 400 µl 30% PEG and divided into cold 40 µl tubes, before 
the tubes were stored at –80⁰C. 
 
3.11.2  Preparation of chemically competent Escherichia coli TOP10 cells 
Chemically competent E. coli TOP10 cells were prepared as follows: 
Materials: 
Ice-cold 0.05M CaCl2 
Ice-cold 0.05M CaCl2, with 15% glycerol  
LB medium 
E. coli TOP 10 cells 
 
Procedure: 
1. A single colony of E. coli TOP10 was used to inoculate 5 ml LB medium, followed by 
overnight growth at 37⁰C.   
2. After diluting the culture to OD600 = 0.1 in 200 ml LB, the culture was incubated at 37⁰C 
to OD600 = 0.4. 
3. In new centrifuge tubes, the cultures were incubated on ice for 10 min, before centrifuged 
at 4000 rpm for 5 min, at 4⁰C.  
4. After removing the supernatant, the pellet was re-suspended in 15 ml ice-cold 0.05 M 
CaCl2, followed by centrifugation at 4000 rpm for 10 min at 4⁰C. 
5. Step 4 was repeated. 
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6. After removing the supernatant, the pellet was re-suspended in 10 ml ice-cold 0.05 M 
CaCl2 with 15% glycerol and incubated in an ice bath for 10 min. 
7. 200 µl portions of competent cells were pipetted into sterile 1.5 ml eppendorftubes and 
immediately stored at –80⁰C. 
 
3.12  Electroporation of Lactobacillus plantarum WCFS1 
Electro-competent L. plantarum WCFS1 cells were electroporated to enhance the uptake of 
plasmids. 
Materials: 
Electroporation cuvettes  
MRSSM 
 
Procedure:  
1. 40 µl containing competent L. plantarum cells were mixed with 5 µl of purified plasmid.  
2. The electroporator Gene Pulser® II and Pulse Controller plus were used with the 
parameters: 
Tension 1,5 kV 
Capacity 25 mF 
Resistance 400 W 
3. The 2 mm cuvette was placed in the electroporator for application of the electric pulse. 
4. 950 µl of ice cold MRSSM was added to the cuvette before transported into 
eppendorftubes.  
5. The tubes were incubated for 2–4 hours at 37⁰C, before plated on appropriate plates 
containing appropriate antibiotics.  
 
3.13 Transformation of chemical competent Escherichia coli 
The uptake of extracellular plasmids by chemical competent E. coli was enhanced through heat 
shock.  
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Materials: 
BHI agar plates containing 200 µl erythromycin  
Plasmid solution 
S.O.C medium 
Chemically competent E. coli TOP10 cells, 200 l portions 
 
Procedure: 
1. A portion of the electro-competent E. coli Top10 cells were mixed in 14 ml Falcon 2059 
Polypropylene Round Bottom tube, with 1–5 µl of the plasmid. The mixture was 
inoculated on ice for 30 min. 
2. The cells were heat shocked at 42⁰C for 1 min and immediately chilled on ice for 2 min. 
3. 250 µl room tempered S.O.C medium were added to the cells, and the solution was 
incubated at 37⁰C, shaking for 1–4 hours. 
4. The cells were spread on agar plates and incubated at 37⁰C overnight.  
 
3.14 Protein production Escherichia coli 
In this study, cells were lysed by combining lysozyme treatment and sonication to retrieve 
intracellular proteins. Lysozymes are enzymes that degrade the peptidoglycan layer in the cell 
wall, leaving the cell more exposed and weakened. Lysozymes disrupt the link between N-
acetylglucosamin (NAG) and N-acetylmuramic acid (NAM), which causes the cell wall to break 
and contributes to cell lysis. Sonication uses a high frequency sound wave that causes cells to 
lyse. The probe’s mechanical energy results in shock waves that spread throughout the 
suspension in short multiple pulses, preventing the suspension from overheating.  
Materials:  
100 mg/ml Lysozyme 
NaPO4 Buffer 
PMSF 
Protease inhibitor cocktails 
Sonics, Vibracell 
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Procedure: 
1. Bacterial cultures that were grown at 18⁰C, were induced by adding arabinose to a final 
concentration of 0.02% at OD600 = 0.5–0.7. 
2. The cultures were induced and incubated overnight at 18⁰C. The cells were then harvested 
through centrifugation at 8000 rpm for 10 min at 4⁰C. While keeping the pellet on ice, the 
supernatant was discarded.  
3. The cell pellet was re-suspended in 15 ml NaPO4 buffer and was centrifuged at 7000 rpm 
for 10 min at 4⁰C. The supernatant was then discarded. 
4. The cell pellet was re-suspended in 15 ml NaPO4 buffer and was added lysozyme to the 
final concentration 0.1 mg/ml. 2 µl PMSF or 1 protease inhibitor cocktail tablet was added 
and the solution was incubated on ice for 20 min.  
5. The solution was sonicated for 20–30 min, 5 sec ON/OFF, with 33% amplitude.  
6. The solution was centrifuged at 7000 rpm for 10 min, before pellet and supernatant was 
divided into two separated tubes.  
 
3.15  Protein purification 
Ni
2+
-NTA (Nickel Nitrilotriacetic Acid) chromatography was used to purify the proteins in this 
study, since these proteins all had His-tags. NTA has four chelating sites, which allows a stable 
interaction between Ni
2+
 and the column matrix. This leaves two free sites to interact with 
functional groups on proteins. If 7 histidine residues (a His-tag) are linked to either the N- or C-
terminus of a protein, such a protein will have a high affinity interaction with Ni
2+
-NTA (Figure 
3.1). 
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Figure 3.1: Interaction between Ni
2+
-NTA matrix of the column and the (His)6 residues in 
the proteins. The interaction point between the column matrix and the His-tag (located either N- 
or C- terminally) is the Ni
2+
, which stabilizes the interaction. See text for more information. The 
picture is taken from (Bævre Heggset 2005).   
 
 
The interaction between the column matrix and the His-tagged proteins separates these proteins 
from the rest of the proteins in the sample (Fig. 3.1), which normally pass right through the 
column. After running the sample through the column, proteins retained in the column can be 
eluted with buffers containing either imidazole (competing to bind the chelating binding sites), or 
with changing pH (leading to a structural change in the proteins). In either way the His-tag 
containing proteins are eluted from the column, often in a highly pure state.  
 
Materials:  
20% Ethanol 
Buffer A: 100 mM Tris HCl pH 7.4.  
Buffer B: 100 mM Tris HCl pH 7.4, 500 mM Imidazole 
Ni-NTA superflow column  
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Procedure:  
1. The column was packed with Ni-NTA superflow beads, and buffer A was run through the 
system with a 1.5 mg/ml flow rate. Care was taken to avoid bubbles in the system.  
2. The sample was run through the system after the entire system contained buffer A. The 
high peak that was detected on the computer’s digital analyzed chromatogram, after the 
sample was added, contained proteins that failed to bind to the column, and was collected. 
3. After the “flow-through peak” was finished, the buffer was changed from buffer A to B. 
4. Peaks detected after the buffer-switch was collected. Proteins that bind to the column are 
expected to end in this peak. 
 
3.16  Gel electrophoresis of proteins 
Polyacrylamide gel electrophoresis (PAGE) separate proteins accorded to their size. In this study, 
Invitrogen’s NuPAGE® Novex Bis-Tris electrophoresis system was used. The LDS Sample 
Buffer contains lithium dodecyl sulphate, which is a Sodium Dodecyl Sulfate (SDS) analogue 
that interferes with non-covalent stabilizing interactions in the proteins, resulting in denaturation 
and introducing a fixed negative charge on each residue. Disulphide bonds are reduced (broken) 
by the addition of a reducing agent such as dithiothreitol (DTT). The negatively charged and 
denatured proteins are then separated by applying an electric field, where the proteins migrate 
towards the positive pole. The smaller proteins meet less resistance and migrate faster than the 
larger proteins, causing the separation. Protein sizes are determined using suitable standards 
(“ladders”). Proteins are visualized by the Gel Doc™ EZ system, which images stain-free gels 
placed on a stain-free tray. In western blotting (see section 3.22), specific proteins are visualized 
using antibodies.  
Materials: 
NuPAGE ® LDS Sample Buffer (4x)  
NuPAGE ® Novex Bis – Tris Gels 
NuPAGE ® Reducing Agent (10x) 
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Procedure:  
1. After adding 7 µl LDS Sample Buffer and 3 µl Reducing Agent to a 10 µl protein sample, 
the mix was heated to 90⁰C for 5 min. 
2. The electrophoresis chamber was assembled, using a proper amount of 1x TAE buffer in 
both the inner and outer chamber. 
3. The heated samples were applied to the wells and run at 300 V for 15 min.  
4. The chamber was disassembled and the gels were released before washed in a plastic tray 
containing dH2O. 
5. After 5 min in dH2O, the gel was placed on a stain-free tray and analyzed by Gel Doc™ 
EZ system. 
 
3.17 Concentrating proteins in a solution 
Ultrafiltration tubes contain a semi-permeable membrane with a chosen defined Molecular 
Weight Cut-Off (MWCO). MWCO normally approximates 50% of the size (expressed in kDa) of 
the protein of interest, to achieve the highest potential protein recovery (which is approximately 
95%). Centrifugation forces the solution through the membrane, only withholding molecules 
larger than the MWCO (GE Health Care 2014). 
Materials: 
Amicon concentrating tubes 
MWCO filter (3 kDa) 
 
Procedure: 
1. After adding the protein samples to the MWCO tubes, the tubes were centrifuged at 
45000 rpm for 30 min or more, until the desire amount of buffer solution remained. 
2. The remaining solution was transferred to Eppendorf tubes and stored at 4⁰C. 
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3.18 Measuring protein concentrations 
Bio-Rad Protein Assay is a dye-binding assay to determine protein concentrations in sample 
solutions. The Bio-Rad Protein Assay Dye Reagent Concentrate, when added to the protein 
sample, changes colour from red to blue. The variation in colour is measured using a 
spectrophotometer (Bio-Rad Laboratories).  
Materials: 
20 mM Tris HCl pH 8.0 
Bio-Rad Protein Assay Dye Reagent Concentrate 
 
Procedure: 
1. Three samples of 799 µl 20 mM Tris HCl pH 8.0 was mixed with 1 µl of the protein 
samples each. 200 µl Protein assay dye reagent concentrate was added and the sample was 
vortexed.  
2. All samples were incubated at room temperature with the protein assay dye reagent 
concentrate for 5 min, letting the dye attach to proteins in the samples, before measuring 
the concentration using the Bradford micro program.  
 
3.19  Recovery of proteins from inclusion bodies  
The formation of inclusion bodies captures unfolded proteins within the cell, where they are 
found in a relatively pure state. Denaturing will improve extraction of proteins from the interior 
of the cell. In this denatured state, the protein’s primary structure (the amino acid sequence) is 
exposed to the extracellular material, potentially revealing pre-hidden structures needed to purify 
the protein (Bævre Heggset 2005). This purifying process is divided into the denaturing part and 
the refolding part.  
Materials:  
6M Guanidium Hydroklorid 
10 mM 2-β-mercaptoetanol (β-ME) 
25 mM DTT 
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20 mM Tris-HCl pH 8.0 
8M Urea 
 
Procedure: 
1. E. coli cultures were grown at 30⁰C to OD600=0.5–0.7 was reached. The cultures were 
then induced with 0.2% arabinose and incubated for 12 hours. 
2. Steps 2–6 in section 3.14 were followed. The resulting cell pellets were diluted in 8 ml 20 
mM Tris HCl pH 8.0 (Bævre Heggset 2005) and divided into 8 Eppendorf tubes.  
3. The Eppendorf tubes were centrifuged at 13. 000 rpm for 10 min at 4⁰ C, and the 
supernatant discarded. 
4. The Eppendorf tubes were labeled 1–8, and added the different denaturants: 
1. 6 M Guanidium Hydroklorid  
2. 6 M Guanidium Hydroklorid + 25 mM DTT 
3. 6 M Guanidium Hydroklorid + 10 mM β-ME 
4. 6 M Guanidium Hydroklorid + 10 mM β-ME + 25 mM DTT 
5. 8 M Urea 
6. 8 M Urea+ 25 mM DTT 
7. 8 M Urea+ 10 mM β-ME 
8. 8 M Urea+ 10 mM β-ME + 25 mM DTT 
All eppendorftubes were added 10 µl 1 M Tris HCl pH 8.0 and 0.0137 g NaH2PO4. 
5. The Eppendorf tubes were incubated at room temperature for 2 hours (occasionally 
vortexed) and centrifuged for 10 min at 13000 rpm. Both the supernatants and the pellets 
were analyzed by SDS-PAGE, to reveal the amount of protein dissolved into the 
supernatant. 
6. Based on these results 8 M urea with no further additions was selected for the 
solubliziation of inclusion bodies.  
The denatured protein was purified by Ni-NTA beaded column, according to section 3.15, the 
only difference being that buffer A and B contained 8 M urea to keep the protein in the denatured 
state during purification.  
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Protein refolding  
Two approaches were used to refold the denatured proteins, both derived from (Bævre Heggset 
2005). Both methods depend on the removal of denaturants (8 M urea); Dialysis rapidly changes 
the proteins’ environment from denaturing to neutral. The proteins are kept in this neutral 
condition for a while. Refolding solutions change the environment from denaturing to neutral in a 
gradual manner, removing denaturants slowly. Depending on the proteins’ nature, one of the 
methods could possibly result in soluble proteins, rather than aggregated proteins (Tsumotoa et 
al. 2003). 
 
Dialysis  
Materials:  
SnakeSkin® Dialysis Tubing  
Spectra/Por® Closures 
 
Procedure: 
1. 1 ml purified denatured proteins in denaturing buffer B (100 mM Tris HCl, pH 8, 500 mM 
imidazole and 8 M Urea), was transferred into the SnakeSkin® Dialysis Tubing. The 
protein solution was kept within the SnakeSkin® Dialysis Tubing using Spectra/Por® 
Closures on both ends of the SnakeSkin.  
2. The SnakeSkin® Dialysis Tubing was then left in a dialysis buffer for two days, 
containing 200x volume 20 mM Tris HCl pH 8.  
3. The SnakeSkin® Dialysis Tubing was then transferred to a new dialysis buffer, with 200x 
volume 20 mM Tris HCl pH 8 and incubated for 3 days. 
4. The proteins were concentrated in 20 mM Tris HCl pH 8 using MWCO tubes (section 
3.17), before analyzing by Native acrylamide gel. 
 
Refolding proteins in refolding-solution  
 
Materials: 
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0.9M arginine  
0.5mM oxidized glutathione 
5mM reduced glutathione 
50mM Tris HCl pH 8.0 
dH2O 
 
Procedure: 
1. 100 ml sample of the refolding solution was made following (Bævre Heggset 2005). The 
refolding solution was divided on two 100 ml beakers, both containing 50 ml of the 
refolding solution.  
2. 1 ml of the denatured and purified protein sample in denaturing buffer B (100 mM Tris 
HCl, pH 8, 500 mM imidazole and 8 M Urea), was poured into one of the 100 ml beakers 
and incubated for 30 min at 4⁰C. 
3. After the incubation, the remaining 50 ml refolding solution was poured into the 100 ml 
beaker, and incubated at 4⁰C for 3 days. The proteins were concentrated using MWCO 
tubes (see section 3.17) in 20 mM Tris HCl pH 8, before analyzing by Native acrylamide 
gel (section 3.20).  
 
3.20  Gel Electrophoresis with Native acrylamide gels 
Native PAGE gels separate proteins under non-reducing and non-denaturing conditions, 
maintaining the protein’s secondary structure and charge natural density. The proteins are 
separated by a charge to mass ratio based on the proteins natural pI (isoelectric point) (Sino 
Biological Inc. 2004).  
Materials:  
NativeMark™ Unstained Protein Standards  
NativePAGE™ Cathode Buffer Additive (2x)  
NativePAGE™ Gel  
NativePAGE™ Running buffer (20x)  
NativePAGE™ Sample Buffer (4x)  
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dH2O  
 
Procedure: 
1. Reactions were set up according to the protocol from the supplier. 2.5 µl NativePAGE™ 
Sample Buffer (4x) were mixed with the appropriate amount of protein sample in an 
Eppendorf tube, because the protein concentration was so low, 15 µl of the protein 
samples were used. dH2O was added to a final volume of 20 µl.  
2. 50 ml of the NativePAGE™ Cathode Buffer Additive (2x) was mixed with 950 ml dH2O, 
and 50 ml of the NativePAGE™ Running buffer (20x) was mixed with 950 ml dH2O. 
3. The NativePAGE™ Running buffer was placed in the outer room, while NativePAGE™ 
Cathode Buffer Additive was placed in the inner room.  
4. The samples were applied into the wells, and the gel run on 150 V for 1.5–2 hours.  
 
 
Coomassie staining of Native gels 
Materials: 
Brilliant Blue R concentrates Electrophoresis Reagent 
 0.1 % (v/v) Coomassie 
 Brilliant Blue R 250 
 50 % (v/v) methanol 
 10 % (v/v) acetic acid 
Destaining solution 
 10 % (v/v) acetic acid 
10 % (v/v) ethanol 
dH2O 
 
 
Procedure:  
1. The Native acrylamide gel was washed in pre-heated dH2O for 1 hour, in plastic trays and 
shake. 
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2. The gel was incubated in pre-warmed Brilliant Blue R concentrates Electrophoresis 
Reagent for 1 hour, shaking.  
3. After removing the Brilliant Blue R concentrates Electrophoresis Reagent, the Destain 
solution was added to the gel. The tray was incubated for 1 hour, with shaking.  
4. The Destain solution was removed and the gel washed with dH2O until the bands were 
visible. The gel was transferred to the white tray before analyzing by the Gel Doc™ EZ 
system. 
 
3.21 Anchoring LysM domain-containing proteins to gram positive bacteria 
Proteins containing LysM domains, produced in E. coli, were incubated with bacterial cells to 
result in proteins being anchored to the peptidoglycan layer.  
 
Materials: 
BHI  
MRS 
Phosphate buffered saline (PBS) 
Table centrifuge 
 
Procedure: 
1. Bacterial cells were grown in appropriate media (Lactobacillus spp. in MRS and B. 
subtilis in BHI), to reach the exponential phase. The cells were harvested through 
centrifugation, and the supernatant discarded. 
2. The pellet was washed twice in PBS, and centrifuged for 2 min in between. The 
supernatant was discarded after each wash. 
3. The cell pellet was diluted in 1 ml PBS, to the final OD600=0.5. The solution was 
centrifuged at 5000 x g at 4⁰C for 3 min before the supernatant was discarded.  
4. The pellet were re-suspended in 1 ml of protein extracts (see Result section for more 
details) and incubated at room temperature for 1 hour (with occasionally vortexing). 
5. The sample was centrifuged for 3 min, at 5000 x g at 4⁰C. The supernatant was discarded, 
and the cell pellet was diluted in 1 ml PBS.  
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6. The sample was centrifuged for 2 min, at 5000 x g at 4⁰C. The supernatant was discarded, 
and the cell pellet was diluted in 1 ml PBS.  
7. Step 6 was repeated 2 times.  
8. The supernatant was discarded and the pellet was analyzed further using flow cytometry 
(section 3.23) or western blot (see section 3.22).  
 
3.22  Western blot analysis 
In blotting, proteins separated according to their size on electrophoresis gels, are transferred to a 
nitrocellulose membrane, by applying an electric current. To detect proteins of interest with 
specific epitopes, a very sensitive detection method is used, called antibody hybridization. The 
membrane has a high affinity towards proteins and to prevent unspecific binding, the membranes 
are blocked before primary antibodies are added. The protein of interest is probed with the 
primary antibody that binds to a specific epitope on the protein. Unbound primary antibodies are 
washed away before the secondary antibodies are added. The secondary antibodies are linked to a 
reporter enzyme, which produces a detectable signal when introduced to the proper substrate. In 
this study chemiluminescent detection was used (see section 3.22.3) 
 
 
Figure 3.2: A schematic illustration of the layers in the iBlot system; transferring proteins 
from the gel to the membrane. The Figure is taken from “iBlot Dry Blotting system user 
manual” (Life technologies™). 
METHODS 
57 
 
Materials: 
Blotting roller  
iBlot™ Anode stack, bottom 
iBlot™ Cathode stack, top 
iBlot™ Disposable sponge  
iBlot™ Dry Blotting system 
iBlot™ Filter paper  
iBlot™ Gel transfer device 
iBlot™ Gel Transfer Stack, Mini 
 
Procedure: 
1. SDS-PAGE gels (see section 3.16) were washed in dH2O for at least 5 min. 
2. The membrane containing anode stack (Figure 3.2) was placed in the gel transfer device, 
placing the gel on top of the membrane.  
3. A wet filter paper with dH2O was placed on top of the gel, and air bubbles trapped 
between the layers were removed with the blotting roller. 
4. The cathode stack containing the copper electrode sited upwards on top of the filter paper. 
5. The disposable sponge was placed in the lid and the transfer device was closed.  
6. Program 3; with the settings 23 V and 7 minutes. After finishing the program, the 
membrane was removed from the transfer device and incubated in dH2O for at least 5 
min.  
7. The membrane was then run through an antibody hybridization process using the SNAP 
i.d. immmuneblotting system (see section 3.22.1).  
 
3.22.1  SNAP i.d. immunodetection 
The SNAP i.d. ® detection system was used to probe all western blots. In this process, the 
antibodies are introduced to the membrane-bound proteins, hybridizing to the proteins containing 
specific epitopes. To speed up the method and give a high-quality protein blot, the SNAP i.d. ® 
detection system uses vacuum to pull the reagents into the membrane. This is a contrast to the 
traditional immunodetection system, which relies on diffusion to help antibodies into the 
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membrane (Figure 3.3).  
 
 
Figure 3.3: Schematic illustration of the difference between immunodetection systems using 
vacuum and systems based on diffusion. The standard method relies on diffusion to slowly 
distribute the reagents, while the SNAP i.d. method uses a strong pulling force driven by the 
vacuum, to rapidly drive the reagents into the membrane. The picture is taken from “SNAP i.d.™ 
Protein Detection System” (Komabiotech 2008). 
 
Materials:  
Blocking Buffer (TTBS/ 1% BSA)  
Primary antibodies: 
         ESAT6 Mouse mcAb (ab26246)  
         Penta - His™ Antibody, BSA free 
Secondary antibodies HRP – Rabbit Anti – Mouse IgG 
SNAP i.d. Detection System 
TTBS 
TTBS/ 0.5% BSA 
 
Procedure: 
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1. The Blot Holder was wetted using dH2O before placing the blotted membrane inside the 
Blot Holder, protein faced down. A wet filter paper was placed at the top, and the holder 
was firmly closed and placed in the SNAP i.d. Protein Detector system device. 
2. 30 ml Block buffer was added, and the vacuum turned on immediately. The vacuum was 
turned off when the well was empty. 
3. 3 ml TTBS/ 0.5% BSA with 2 µl/ml primary antibody was incubated in the well for 10 
min. 
4. The well was washed with 3x 10 ml TTBS with the vacuum on continuously; when the 
well was empty the vacuum was turned off. 
5. 3 ml TTBS/ 0.5% BSA with 0.04 µl/ml secondary antibody was incubated on the well for 
10 min. 
6. Step 4 was repeated.  
7. The membrane was removed from the blot holder and placed in an appropriate detection 
agent (section 3.22.2). 
 
3.22.2   Chemiluminiscent detection of protein 
Chemiluminiscence was used to visualize proteins on the membranes, labeled with the secondary 
antibody. The secondary antibody contains horseradish peroxidase (HRP), which oxidizes the 
appropriate substrate when added to the reaction solution. This results in an emission of light 
which is captured on an x-ray film.  
 
Materials: 
CL-Xposure™ Film 
Developer solution 
Fix solution 
Luminol/Enhancer  
Stable Peroxide Buffer 
Solution SuperSignal® West Pico Chemiluminiscent Substrate 
 
Procedure: 
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1. 3.3 ml of Luminol/Enhancer Solution was mixed with 3.3 ml of Stable Peroxide Buffer to 
prepare the substrate working solution. 
2. After incubating the membrane in a substrate working solution for 5 min, in plastic trays, 
the membrane was placed in plastic foiled covered lightproof film cassette, leaving the 
protein-side of the membrane facing upward. 
3. In the dark room, a CL-Xposure™ Film was cut in an appropriate size and placed on top 
of the membrane, before closing the cassette for 1–15 min, depended on the strength of 
the chemiluminiscens signal. 
4. After incubation in developer solution for 2 min, the film was incubated in the fix solution 
for additional 2 min.  
5. The film was then washed with water and air dried.  
 
3.22.3   Stripping and re-probing the nitrocellulose membrane from western blot analysis 
Materials: 
Restore™ Western Blot Stripping Buffer 
TTBS 
 
Procedure: 
1. The previously blocked, probed and developed nitrocellulose membrane from western 
blot (see section 3.22, 3.22.1 and 3.22.2) was stored in TBS (4⁰C), before the membrane 
was stripped. 
2. The blot was incubated in Restore™ Western Blot Stripping Buffer for 30 min at room 
temperature. 
3. The blot was washed with TTBS and new antibody hybridization and detection was 
performed (see section 3.22.1 and 3.22.2). 
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3.23  Detection of surface antigens using FITC-labelled secondary antibodies 
and flow cytometry 
Proteins of interest contain specific epitopes that are recognized by primary antibodies, which 
again, are recognized by secondary antibodies (e.g. anti-mouse IgG). In this experiment, the 
secondary antibodies were labeled with the fluorochrome fluorescein isothiocyanate (FITC). 
FITC-labeled cells can be detected using flow cytometry.  
Flow cytometry (Figure 3.4) detects the fluorescence and the scattered light from a single cell 
that passes (one at a time) through a laser beam. The light scatters in all directions, and are 
monitored by detectors. Light scattered forward gives information about the cells’ size, while 
light scattered sideways gives information about the cells’ intracellular properties, as the 
granularity of the cell. The laser beam is also called an excitation light, which has the possibility 
to excite antigens containing fluorochormes (Lea 2006); the potential resulting fluorescence is 
detected by a mirror- and filter-system. By combining the data collected, a cell population may be 
analyzed. 
 
 
Figure 3.4: The schematic illustration of the principles of a flow cytometry. The cells are led 
through a laser beam, one by one, and the information retrieved from the analysis of the cells 
depends on the scattered light from the cell surface. The optics gathers and directs the light, and 
the computer system converts the data retrieved from the detectors into digital data that are 
analyzed. The picture is taken from (Tjåland 2011) 
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Materials: 
PBS 
PBS/ 2% BSA 
Primary antibody ESAT6 Mouse mcAb (ab26246) 
Secondary antibody Anti – Mouse IgG (FITC) 
 
Procedure: 
1. Bacterial cells where prepared and charged with LysM-containing proteins as described in 
section 3.21, step 1–8. 
2. After re-suspending the cells in 50 µl PBS / 2% BSA and 0.4 µl of primary antibodies, the 
solutions were incubated for 30 min on ice. The solutions were then centrifuged at 5000 x 
g, for 2 min, at 4⁰C. 
3. The samples were washed with1 ml PBS/ 2% BSA and centrifuged for 2 min at 5000 x g 
at 4⁰C and the supernatant discarded. 
4. Step 3 was repeated 2 times.  
5. After re-suspending the cells in 50 µl PBS / 2% BSA and 0.8 µl of secondary antibodies, 
the solutions were incubated for 30 min on ice. The solutions were then centrifuged at 
5000 x g, for 2 min, at 4 ⁰C. 
6. The samples were washed as in step 3 and 4. 
7. The stained pellets were re-suspended in 100 µl PBS before immediately analyzed by 
MacsQuant® Analyzer (Miltenyi Biotech) and MacsQuantify™ software. 
 
3.24 Protein production in Lactobacillus plantarum  
Materials:  
Erythromycin 10 µg/ml 
Inducing peptide SppIP 
MRS medium 
PBS buffer 
 
Procedure: 
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1. Overnight cultures of L. plantarum harboring the appropriate plasmid were grown in 10 
ml MRS medium containing the final concentration of 10 µg/ml Erythromycin at 37⁰C. 
2. The overnight cultures were diluted in 50 ml pre-warmed MRS medium containing the 
final concentration of 10 µg/ml Erythromycin, to OD600=0.1 followed by incubation at 
37⁰C. 
3. Before the cultures reached an OD600 of 0.3, they were induced by adding the inducing 
peptide, SppIP, to a final concentration of 25 ng/ml. 
4. The cultures were incubated for 2 or 5 hours and chilled on ice for 10 min, for the cells to 
stop growing. 
5. The cells were centrifuged at 5000 x g for 10 min at 4⁰C, and the supernatant discarded. 
6. The pellets were re-suspended in 1x PBS, and diluted to a final OD600 = 0.5, before a pre-
stained protocol for flow cytometry was followed (see section 3.23), or the cell pellet was 
disrupted using glass bead for subsequent western blot analysis (see sections 3.25 and 
3.22, respectively).   
 
3.25  Destructions of cells using glass beads 
Glass beads of pre-determined amount and size are used to disrupt cells when shaken vigorously. 
This causes the glass beads to collide with the cells in the sample, finally disrupting the cells and 
releasing the interior biomolecules. This method makes it possible to determine intracellular 
protein production in bacteria (e.g. L. plantarum).  
Materials: 
FastPrep tubes  
Glass beads (106 microns and finer)  
PBS  
 
Procedure: 
1. L. plantarum cultures harboring the appropriate plasmids were harvested and washed as 
described in section 3.24, step 1–6.  
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2. The cell pellet was diluted in 1 ml PBS and transferred to a cooled FastPrep tube 
containing 1.5 g glass beads. 
3. The FastPrep tube was run in the FastPrep® FP120 Cell Disrupter, keeping the speed 6.5 
m/s for 45 sec. 
4. The tube was centrifuged at 13000 rpm for 30 sec, and the supernatant aspired carefully, 
before transferred to a new Eppendorf tube.  
5. Step 4 was repeated. 
6. The cell-free protein extract was stored at –20⁰C. 
 
3.26 Prepare cells for freeze drying  
Freeze drying uses vacuum to dry at approximately –40⁰C (OPS DIAGNOSTICS 2001), which 
causes distress on cells and  proteins. Therefore a freeze drying medium is added to help protect 
cells and proteins. The combination resulting in the best protection varies with protein type and 
bacterial strain (Leslie et al. 1995). In this study, bacterial cell pellets harvested through 
centrifugation were diluted in freeze dry medium, containing skimmed milk and fructose 
(Øverland 2013) to help preserve the cultured cells.  
 
Material:  
PBS 
Freeze dry medium: 
11% (w/v) skim milk  
12 g/L Fructose 
 
Procedure: 
1. Bacterial cells charged with LysM-containing proteins were prepared as in section 3.21, 
step 1–8. The cell pellets were further washed 3x using PBS, before the supernatant was 
discarded. 
2. The sample was centrifuged at 5000 x g, at 4⁰C for 10 min, before the supernatant was 
discarded and the pellet re-suspended in 1 ml PBS.  
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3. The sample was centrifuged at 5000 x g, at 4⁰C for 3 min, before the supernatant was 
discarded and the pellet re-suspended in 1 ml PBS.  
4. Step 3 was repeated two times.  
5. The cell pellet was added 1 ml freeze dry medium and freeze dried overnight. 
6. The freeze dried cells were stored in darkness at room temperature. 
7. To hydrate the cells, 1 ml sterile dH2O was added. 
 
3.27  Lysozyme treatment 
Proteins that are embedded in the cell wall structure could be difficult to obtain by primary 
antibodies, which results in undetected proteins when analyzed by flow cytometry or microscopy. 
Therefore cells with potentially embedded proteins were treated with lysozyme, which disrupts 
the peptidoglycan layer, possibly revealing the buried proteins beneath. 
Materials: 
Lysozyme 100 mg/ml  
PBS 
Procedure: 
1. L. plantarum cultures harboring appropriate plasmids were harvested and washed 
according to section 3.24, Step 1 –6. 
2. After dissolving the pellets in 300 µl PBS and 200 µl lysozyme, they were incubated at 
37⁰C for 30 min. Negative samples were included by adding 500 µl PBS only, before 
incubating at 37⁰C for 30 min.  
3. The cells were washed 3x with PBS and centrifuged at 5000 x g for 2 min at 4⁰C, in 
between.  
4. The cells were then pre-stained for flow cytometry (see section 3.23).  
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4. RESULTS 
 
4.1 Intracellular production of 3014-TB and 2162-TB in Escherichia coli 
3014-TB and 2162-TB are proteins combining the promising antigens Ag85B and ESAT6 with 
the LysM anchoring domains; 3014 (contains a single LysM domain) and 2162 (contains two 
LysM domains). Ag85B and ESAT6 were selected due to their promotion of high immune 
responses against tuberculosis (TB) in mice, guinea pig and non-human primate models 
(Langermans et al. 2005; Olsen et al. 2001; Olsen et al. 2004). The lysM domains were retrieved 
from the N-terminal of the gene fragment encoding Lp_3014 and Lp_2162 (Fig. 1.3), the signal 
sequence (pSIP) located at the N-terminal of the LysM domains were replaced with a 7 histidine, 
His-tag. This was done to ensure the intracellular production in E. coli and the possibility to 
purify the protein. The LysM domains were fused to the N-terminal of the antigens (Ag85B-
ESAT6), and a DC-targeting peptide was added to the C-terminus of these fusion proteins to 
promote targeting of dendritic cells (Tyler et al. 2013).  
 
4.1.1 Construction of 3014-TB 
Constructs from previous studies, pLp_AG85B_ESAT6-DC (Øverland 2013) and 
pLp_3014Gag24p (Urdal 2013) (The plasmids are listed in Table 2.4) were used as templates to 
generate the fragments needed to construct the plasmid p3014_Ag85B-ESAT6-DC for production 
of 3014-TB (Figure 4.1). The template pLp_3014Gag24p were used to generate the fragment 
3014_LysM, using primers 3014_F and 3014_R, while pLp_AG85B_ESAT6-DC were used to 
generate the fragment Ag85B_ESAT6-DC, using primers AG85Fus3014_F and AGDCHisR. The 
two fragments were fused together by a PCR reaction to create the final fragment, 3014-Ag85B-
ESAT6-DC (Figure 4.1)  
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Figure 4.1: Strategy for generating the fragments 3014_LysM and Ag85B-ESAT6.  The 
PCR reaction with pLp_3014Gagp24 as template and 3014_F and 3014_R as primers resulted in 
the 3014_LysM fragment. Another PCR reaction with Lp1262-AG85B-ESAT6-DC as template 
and primers AG84Fus3014_F and AGDCHisR resulted in the Ag85B-ESAT6 fragment. The two 
PCR-fragments have overlapping ends and were fused together with a PCR reaction with primers 
Ag85Fus3014F and Ag85DCHisR, resulting in the final fragment, 3014-Ag85B-ESAT6-DC. The 
His-tag is located at the 3’-end in the final fragment 3014-Ag85B-ESAT6-DC and is visualized in 
green. 
 
The gene fragment 3014-Ag85B-ESAT6-DC was ligated into a BglII and EcoRI digested pBAD, 
yielding the final construct called p3014-Ag85B-ESAT6-DC (Figure 4.2). Purified pBAD 
plasmids were digested using BglII and EcoRI, resulting in two fragments with the sizes 50 bp 
and 3964 bp. The fragments were separated according to size on agarose gel, leaving the larger 
fragment (3964 bp) free to be extracted and purified (Figure 4.2).  
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Figure 4.2: The cloning strategy for 3014-TB. The BglII and EcoRI digested and purified 
pBAD fragment (3964 bp) were, by using In Fusion cloning reaction, cloned with the gene 
fragment 3014-Ag85B-ESAT6-DC, yielding the final construct 3014-TB. 
 
4.1.2  Construction of 2162-TB 
A second construct, 2162-TB differs from 3014-TB only in the N-terminal anchor. The gene 
fragment 2162_SVUSP used in the second construct contains two LysM domains, separated by a 
PST linker region (Figure 1.3). C-terminally of the second LysM domain is a short PST linker 
sequence of 17 amino acid residues, which was included to create a proper distance between the 
LysM anchors and antigens. Hopefully, by elongating the distance between the LysM domains 
and the Ag85B-ESAT6-DC (from Lp_3014 to Lp_2162, this distance increases 1.5 times); this 
would yield the proper distance for the optimal binding-affinity of LysM domain and for the N-
terminus His-tag.  
3014-TB was used as the starting point to construct 2162-TB. 3014-TB was digested with SalI 
and BglII (Figure 4.2), and the resulting 5600 bp fragment was isolated from the gel. The 
genomic DNA of L. plantarum was used as template to yield the gene fragment 2162_SVUSP, 
using the primers 2162_USP_F and 2162_SVUSP_R (Figure 4.3). The BglII and SalI digested 
3014-TB, yielding the 5600 bp pBAD fragment were, using In Fusion reaction, cloned with the 
gene fragment 2162_SVUSP, producing the final construct 2162-TB (Figure 4.3). 
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Figure 4.3: The cloning strategy for 2162-TB. The genomic DNA of L. plantarum was used as 
a template to extract 2162_SVUSP with the primers 2162_USP_F and 2162_SVUSP_R. The 
digested 3014-TB with the restriction enzymes BglII and SalI, was in Fusion cloned with the 
PCR-retrieved fragment 2162_SVUSP, to result in the complete plasmid called 2162-TB. The N-
terminus His-tag is visualized in green.  
 
The plasmids, 3104-TB and 2162-TB, were transformed into chemically competent E. coli 
TOP10 cells, transformants were selected using ampicillin resistance, to locate the cells 
harboring the pBAD-derivatives. Transformants containing the correct plasmids (as assessed by 
colony PCR) were cultured for long-term storage as glycerol stocks at –80⁰C.   
 
4.2 Protein expression 
The use of Escherichia  coli strains to produce proteins in large quantities before purification is a 
commonly used method (Eckert et al. 2006; Ohnuma et al. 2007; Olsen et al. 2001; Tyler et al. 
2013), and was therefore chosen in this study to produce 3014-TB and 2162-TB. E. coli cells 
harboring the plasmid, 3014-TB, were used to optimize the intracellular production of 3014-TB 
in E. coli.  
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4.2.1 Intracellular expression of 3014-TB in Escherichia coli 
Protein production in E. coli was run though series of optimizations, due to the production of 
3014-TB as inclusion bodies (see section 3.19 and Fig. 4.5). By varying the growth temperature 
(from 18⁰C–37⁰C), the arabinose concentration (0%–20%) used to induce the expression of 
3014-TB, and the hours incubated (4–24 hours) after induced, hopefully, 3014-TB would avoid 
resulting in inclusion bodies.  
E. coli cells were grown in 500 ml (BHI medium) cultures, in the temperatures 37⁰C, 30⁰C and 
18⁰C. E. coli has an optimal growth temperature of 37⁰C; however, by using lower growth 
temperatures, the growth rate was reduced. The reduced growth rate of the E. coli cells increased 
the time for the proteins (as 3014-TB) to fold properly, and avoided the issue of 3014-TB being 
produced as inclusion bodies. The expression of the gene fragment, 3014-TB, in E. coli cells was 
controlled by an L-arabinose promoter system, araBAD (Greenfield et al. 1978), which uses 
arabinose as the effective inducer. E. coli cells were initially induced with arabinose 
concentrations ranging from 0–20% (Figure 4.4 and 4.5). The time given to produce 3014-TB in 
E. coli cells, after induced with arabinose, was ranging from 4–24 hours (Figure 4.4 and 4.5).  
Firstly, E. coli cells were grown in 10 ml cultures at 37⁰C and 30⁰C, where each culture was 
induced using the arabinose concentrations ranging from 0–20% (0%, 0.002%, 0.02%, 0.2%, 
2%, 20%). After inducing the E. coli cells, each culture was divided into two tubes, each 
containing 5 ml of the original E. coli culture. One of the 5 ml E. coli cultures was incubated for 
4 hours after induced, while the other one was incubated for 24 hours. The culture that was 
incubated for 24 hours, in contrast to the culture incubated for 4 hours, revealed a higher total 
protein yield, and was therefore the incubating time used for incubation in the following work.  
After the incubation of cells for 24 hours, the E. coli cells were disrupted using sonication. After 
5 min of sonication, the cultures were divided into supernatants and cell-pellet using 
centrifugation; both were run on SDS-PAGE (Figure 4.4 and 4.5). A negative control was 
included to all experiments conducted in this work; E. coli TOP10 cells harboring a pBAD-
derivative not expressing the antigens Ag85B-ESAT6-DC.  
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Figure 4.4: SDS-gels of cell extracts from cells harboring 3014-TB harvested 24 hours after 
induced with the indicated amounts of arabinose and grown at the indicated temperatures. 
The expected size of the overexpressed protein, 3014-TB is 56 kDa, and the band corresponding 
to this size is indeed observed in some of the samples. Negative control; were grown at 30⁰C and 
induced with 20% arabinose.  
 
Figure 4.4 depict that soluble 3014-TB was obtained in some of the cultures. Cultures grown at 
30⁰C had the highest amount of soluble protein, indicating that the reduced growth rate at this 
temperature increased the amount of properly folded proteins. Analysis of the pellets obtained 
during the cell disruption procedure, showed that several of the samples contain large amounts of 
insoluble 3014-TB (Figure 4.5). Thus, inclusion bodies seem to be formed. 
 
 
 
56 kDa 
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Figure 4.5: SDS-gel of cell pellets from cells harboring 3014-TB harvested 24 hours after 
induced with the indicated amounts of arabinose and grown at the indicated temperatures. 
The expected size of the overexpressed protein, 3014-TB is 56 kDa, and the band corresponding 
to this size is indeed observed in some of the samples, as inclusion bodies. Negative control; 
were grown at 30⁰C and induced with 20% arabinose. 
 
Samples revealing the lowest production of inclusion bodies were the cultured grown at 30⁰C 
and induced with low arabinose concentrations, as 0% and 0.002% (Figure 4.5). Figure 4.4 
reveals that the cells grown at 30⁰C, induced with the highest arabinose concentrations (2% and 
20%), produces soluble proteins at 56 kDa, surprisingly the band at 56 kDa were not detected 
using western blotting (analyzed using the antibodies ESAT6 Mouse mcAb (ab26246) and 
Penta-His™ Antibody, BSA free, hereafter named anti-ESAT6 and anti-His, respectively).  
Further optimization were therefore tried to hopefully achieve soluble 3014-TB. Finally, by 
decreasing the growth temperature to 18⁰C, induced using arabinose concentrations ranging from 
56 kDa 
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0% –0.4% (0%, 0.02%, 0.2%, 0.3 % and 0.4%), soluble 3014-TB was detected on SDS-PAGE 
(Figure 4.6). 
 
 
 
 
 
Figure 4.6: SDS-gels of cell extracts from cells harboring 3014-TB grown at 18⁰C, induced 
with the indicated amounts of arabinose and harvested after the indicated time of 
incubation. The expected size of the overexpressed protein, 3014-TB is 56 kDa, and the band 
corresponding to this size is indeed observed in some of the samples. The highest yield of 3014-
TB is marked; these are induced with 0.02 % arabinose and harvested after 6 and 12 hours. 
Negative control; were grown at 18⁰C, induced with 0.02% arabinose and harvested after 12 
hours. 
 
The samples revealing the highest production of soluble 3014-TB were detected in the samples 
containing E. coli cells grown at 18⁰C, induced with the final arabinose concentration 0.02 % 
and harvested after incubating for 6 and 12 hours (Fig. 4.6). Western blots confirmed that the 
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band at ca. 56 kDa observed in these samples, depicted in Figure 4.6, indeed is 3014-TB 
(Appendix, Fig. A1). 
The following conditions were used to produce soluble 3014-TB in E. coli cells harboring the 
3014-TB; the cells were grown in 18⁰C, induced with 0.02% arabinose followed by incubating 
for 12 hours (cells were incubated for 12 hours after induced for reasons concerning convenience 
during the work period). These optimal conditions were used in all further attempts to produce 
3014-TB in E. coli. 
 
4.2.2 Intracellular expression of 2162-TB in Escherichia coli 
Producing soluble 2162-TB in E. coli TOP10 cells, followed the optimized conditions 
discovered for the production of soluble 3014-TB, as described in section 4.2.1.  Soluble 2162-
TB was indeed detected using western blotting, as depicted in Fig. 4.7, when grown at 18⁰C, 
induced with 0.02% arabinose followed by 12 hours incubation.  
 
 
 
 
 
Figure 4.7: Western blot, using anti-ESAT6, showing cell extracts from cells harboring 
2162-TB grown at 18⁰C, induced with 0.02 % arabinose, followed by incubation for 12 
hours. The expected size of the overexpressed protein 2162-TB is 60 kDa, and the band 
corresponding to this size is indeed observed in the sample.  
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The following conditions were used to produce soluble 2162-TB in E. coli cells harboring the 
2162-TB; the cells were grown at 18⁰C, induced with 0.02% arabinose followed by incubating 
for 12 hours. These optimal conditions were used in all further attempts to produce 2162-TB in 
E. coli. 
 
4.3 Purification of proteins from cell extracts of E. coli  
3014-TB and 2162-TB were purified from cell-free protein extracts of E. coli cells, using Ni-
NTA columns, as described in section 3.15.  
 
4.3.1 Purification of 3014-TB  
Protein extracts from E. coli cells grown at 18⁰C, induced with 0.02% arabinose and harvested 
after 12 hours incubation, were used as a starting point for purification of 3014-TB, using Ni-
NTA column. Purifications of E. coli protein extract containing soluble 3014-TB, revealed, using 
Western blotting (data not shown), no detectible soluble 3014-TB in the eluate. Therefore were 
several variations in the protocol tried. Buffer A would usually contain low concentrations of 
imidazole (100 mM) to prevent unspecific interactions. We attempted to reduce the starting 
imidazole concentration to 0 mM in order to prevent competition for 3014-TB to interact with 
the Ni-NTA beads. To release bound 3014-TB, the highest imidazole concentration (500 mM) 
was used in Buffer B (Fig. 4.8). 
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Figure 4.8: Western blot, using anti-His antibodies, showing the result of purification of 
3014-TB from cell extracts from E. coli. The sample type is indicated above the lanes, and the 
sample size was 10 µl for all. The 3014-TB protein appears in a full-length form (56 kDa) in the 
flow through. Note that no bands were detected in the eluate. 
 
Also, with this buffer system (buffer A contains 1 M Tris HCl pH 7.4 and buffer B contains 1 M 
Tris HCl pH 7.4 and 500 mM imidazole), all 3014-TB was found in the flow through fraction, 
when analyzed by Western blotting using both anti-ESAT6 (data not shown) and anti-His (Fig. 
4.8), meaning that 3014-TB still did not bind to the Ni-NTA. This observation strengthened the 
idea that the His-tag in folded 3014-TB, somehow is embedded. 
In subsequent experiments, attempts were made to release the potential embedded His-tag by a 
change in pH. Histidine as a positively charged amino acid, were tried released from the folded 
protein structure with a pH change in the buffers (A and B) from 7.4 to 8 (Fig. 4.9).  
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Figure 4.9: Western blots, using anti-His, showing the result of purification of 3014-TB 
from E. coli cell extract, purified in pH 8. The sample type is indicated above the lanes and the 
sample size was 10 µl for all. The 3014-TB protein appears in a full-length form (56 kDa) in the 
flow through. Note that no bands were detected in the eluate.  
 
The variation of pH in the buffer solution did not lead to improved purification of 3014-TB (Fig. 
4.8). Further elevation of pH values were not tested, since pH > 8 could affect the complete 
protein structure and cause denaturation.  
Previous studies revealed that LysM domains in plant proteins bind to chitin (Onaga & Taira 
2008). Although the same has never been observed for bacterial proteins containing LysM 
domains, an attempt was made to purify 3014-TB using chitin beads. Chitin beads were mixed 
with protein extract in Eppendorf tubes, and incubated at room temperature for 10 min. After 
centrifugation, the supernatant was collected, representing the flow through. Buffer solution 
containing 40 mM Tris Hcl pH 7.4 and 4 M ammonium sulphate was then added to the chitin 
beads and after incubating for 10 min, the new supernatant was collected by centrifugation. SDS-
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gels showed that also in this case, 3014-TB appeared in the flow through (data not shown), 
suggesting that the LysM used in this study do not bind to chitin.   
In an alternative approach attempts were made to solubilize 3014-TB from inclusion bodies, 
followed by purification under denaturing conditions. This would hopefully increase the 
possibility to purify the proteins provided that it would be possible to subsequently regain their 
structure under refolding conditions. For this purpose pellets harvested from E .coli cultures 
grown at 30⁰C, induced with 0.2 % arabinose, and incubated for 26 hours (Fig. 4.5), were 
denatured for purification. Several denaturing conditions were tested to dissolve 3014-TB 
(Bævre Heggset 2005) (see section 3.19 for details). Incubation with 8 M urea gave the highest 
yield of resolved 3014-TB (data not shown) and protein solubilized in this manner was subjected 
to purification (Fig. 4.10).  
 
 
 
 
 
 
 
Figure 4.10: SDS-gels showing the result of the purification of E. coli protein extract 
containing solubilized 3014-TB, using 8 M urea.  The 3014-TB protein was kept in a 
solubilized state during the purification, by using buffers containing 8 M urea. 3014-TB appears 
as a full-length protein (56 kDa) in both the flow through and the eluate, though a higher 
percentage of solubilized 3014-TB is found in the eluate.  
56 kDa 
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Soluble 3014-TB was almost completely purified using 8 M urea as the denaturant during 
purification (Fig. 4.10), resulting in the His-tag no longer being embedded in the protein 
structure, and, is therefore free to interact with the Ni-NTA beaded column. Two refolding 
strategies were tested in the attempt to obtain a soluble 3014-TB in the absence of denaturants. 
Refolding by dilution in “Refolding solution” (Bævre Heggset 2005), led to protein precipitation, 
while refolding using dialysis resulted in soluble 3014-TB (data not shown). Though soluble, 
3014-TB was no longer detectable at the cell surface of L. plantarum (data not shown). The final 
purpose of soluble 3014-TB was to bind to gram positive bacteria, such as L. plantarum (see 
section 1.5.2); therefore, 3014-TB was given as E. coli total protein extracts in the following 
binding-studies (see section 4.4).  
 
4.3.2 Purification of 2162-TB  
Considering the problems met when working with 3014-TB, two candidates of 2162-TB were 
made; these were named 2162-TB_L and 2162-TB_S. The difference between the two 2162 
constructs is the length of the PST linker region between the last LysM domain and the Ag85B-
ESAT6-DC antigen (Fig. 1.3, Lp_2162; the area after the last LysM domain). A longer linker 
region could potentially avoid the embedded His-tag that potentially occurred in 3014-TB 
(section 4.3.1). The last PST linker in 2162-TB_L, separating the last LysM domain from the 
antigen, is 240 amino acid residues long, while the last PST linker region in 2162-TB_S only 
contains 17 amino acid residues. The two variants of 2162-TB were produced intracellularly in 
E. coli according to the optimal conditions described in section 4.2.2 (i.e. grown in 18⁰C, 
induced with 0.02 % arabinose followed by incubating for 12 hours.). The protein extracts were 
applied onto Ni-NTA columns using the optimal buffer combination; buffer A containing 1 M 
Tris HCl pH 7.4, and buffer B containing 500 mM imidazole and 1 M Tris HCl pH 7.4 (see 
section 4.3.1). Following the purification of 2162-TB, the samples were analyzed by SDS-PAGE 
(Appendix, Fig. A2), and the presence of 2162-TB was verified by western blotting, using 
antibody anti-His (Fig. 4.11).  
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Figure 4.11: Western blot showing results of the purification of the two variants of 2162-TB 
from E. coli cell extract, using anti-His. The sample type is indicated above the lanes and the 
sample size was 10 µl for all. The 2162-TB_S protein appears both in a full-length form (60 
kDa) and a punctuated form (35 kDa), while 2162-TB_L protein only appears in the punctuated 
form (35k Da). Note that 2162-TB_S protein is detected in the eluate as a full-length protein (60 
kDa).  
 
The protein 2162-TB_S was depicted in a punctuated form (35 kDa) in the flow through, and in 
a full-length form (60 kDa) in both the flow through and the eluate (Fig. 4.11). Western blotting, 
using anti-ESAT6 to verify 2162-TB_S, only reveals the full-length protein of 60 kDa in the 
eluate, which implies that only the full-length protein of 2162-TB_S was purified. 
The N-terminus of the 2162-TB_L protein was the only fragment of 2162-TB_L depicted (35 
kDa) in Figure 4.11, using anti-His, which indicates that 2162-TB_L was either 
degradation/cleaved off or not fully expressed. Western blotting using anti-ESAT6, detected no 
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bands in either flow through or eluate, indicating that the longer PST linker region in 2162-TB_L 
is exposed for cleavage. With this in mind, the 2162-TB_L was discarded and the 2162-TB_S 
were used further (referred to as 2162-TB hereafter).  
After purification, purified 2162-TB was mixed with living L. plantarum cells, to potentially 
bind the cell surfaces. The protein concentration of purified 2162-TB was measured to be 1.67 
mg/ml, which were too low to result in detectable amounts of 2162-TB at the cell surfaces of 
living L. plantarum cells (data not shown). Therefore, the total protein extract of E. coli 
containing soluble 2162-TB were given in the following binding-studies (see section 4.4). 
 
4.4 Anchoring of 3014-TB and 2162-TB to the cell surface of living bacteria 
Due to the problems faced during purification, both 3014-TB (Fig. 4.6) and 2162-TB (Appendix, 
Fig. A2) were given as total protein extracts when mixed with living bacteria. Protein extracts 
from E. coli containing either 3014-TB or 2162-TB were stored in 4⁰C, or used immediately to 
bind to gram positive bacteria. Living L. plantarum cells (Table 2.3) were used as delivery 
vehicles, due to the peptidoglycan layer. Total protein extracts of E. coli containing either 3014-
TB or 2162-TB was mixed with L. plantarum cells, to determine if 3014-TB and 2162-TB was 
capable to bind the cell surfaces of living L. plantarum. Different protocols were tested to 
determine the potential optimal binding conditions.  
Cells harvested from overnight cultures of L. plantarum were washed with PBS, and the cell 
pellets were used in the bindings-studies. 1 ml of total protein extracts containing either 3014-TB 
or 2162-TB, with a total protein concentration varying from 8.8 mg/ml to 11.7 mg/ml, was 
mixed with the washed cells from 1 ml of overnight culture, followed by incubation at room 
temperature for 30–60 minutes (see section 3.21 for more details).  
 
4.4.1 Incubating L. plantarum with 3014-TB proteins 
After co-incubating protein extracts from E. coli cells containing 3014-TB with L. plantarum 
cells for 30 min at room temperature (see section 3.21, for more details), the cells were harvested 
through centrifugation. The resulting cell pellet was washed 3 times by adding 1 ml PBS, before 
vortexing and centrifugation; the supernatant after each centrifugal run was saved, resulting in 4 
RESULTS 
82 
 
supernatants (called supernatant 1–4 hereafter). The same protocol was followed for the co-
incubation of total protein extracts containing 3014-TB and L. plantarum cells for 40, 50 and 60 
min. The goal was to potentially find the conditions of incubation that yielded the highest 
amount of detectable 3014-TB at the cell surface of L. plantarum, therefore, L. plantarum 
harvested in both stationary phase and exponential phase was used to co-incubate with 3014-TB. 
After incubation, the final cell-pellets incubated in 30–60 min were analyzed by western blotting, 
using anti-ESAT6 (Figure 4.12). 
 
 
 
 
 
 
 
Figure 4.12: Western blot, using anti-ESAT6, showing results following the co-incubation 
of protein extracts containing 3014-TB from E. coli with living L. plantarum harvested in 
the stationary (S) or exponential (E) phase. 3014-TB was incubated with L. plantarum for 30 
to 60 min at room temperature. All cell samples reveal 3014-TB (56 kDa) displayed at the cell 
surface of L. plantarum. Negative control; L. plantarum harvested in exponential phase, 
incubated for 60 min with protein extracts from E. coli containing a pBAD-derivative, not 
expressing the Ag85B-ESAT6-DC antigen. 
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3014-TB was depicted to bind to the cell surface of L. plantarum cells, when analyzed by 
western blotting, using anti-ESAT6 (Fig. 4.12) and anti-His (data not shown). 3014-TB binds to 
living L. plantarum after 30 min, and by increasing the incubation period thus increases the 
amount of the protein 3014-TB displayed on the cell surface of L. plantarum (Fig. 4.12). The 
goal was to bind all soluble 3014-TB in the protein extract from E. coli to the cell surfaces of L. 
plantarum cells, therefore, after 1 hour of incubation the supernatants 1–4 were analyzed by 
western blotting, using anti-ESAT6 (Appendix, Fig. A3); unbound 3014-TB would be detected 
in supernatant 1, while poorly bound 3014-TB would be detected in any of the three supernatants 
2–4. 3014-TB was not depicted in the supernatants 1–4 (Appendix, Fig. A3), and therefore, 60 
min of incubation were used in the following bindings-studies.    
Protein extracts containing 3014-TB incubated for 60 min with L. plantarum cells, were using 
the total protein concentration of 11.7 mg/ml. However, by gradually increasing the total protein 
concentration to 44 mg/ml, thus resulted in the gradual increase of the amount of 3014-TB 
displayed at the cell surface, analyzed by western blotting (data not shown). The detectable 
amounts of 3014-TB at the cell surface were not depicted to increase when the total protein 
concentrations used were exceeding 44 mg/ml (data not shown). For simplicity, 11.7 mg/ml of 
the total protein concentrations of protein extracts containing 3014-TB were used in the 
following work.  
 
4.4.2 Unspecific interactions to the cell surface of Lactobacillus plantarum 
The use of protein extracts containing 3014-TB or 2162-TB rather than the purified 3014-TB or 
2162-TB could result in potential background signals; by interpreting the potential bound 
additional substances of the protein extract (e.g. proteins not containing TB-antigens) to the cell 
surfaces of L. plantarum cells, as positive signals. Negative controls were treated equally as the 
sample containing 3014-TB and 2162-TB (described in section 4.4.1); 1 ml of protein extracts 
were incubated for 1 hour with living L. plantarum cells harvested in exponential phase. In this 
manner, the potential unspecific interaction to the cell surfaces of L. plantarum interpreted as 
positive signals would be detected. Four negative controls were tested in this work, analyzed by 
flow cytometry; L. plantarum WCFS1 not mixed with protein extracts (called L. plantarum only) 
and L. plantarum WCFS1 mixed with protein extracts from; 
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- E. coli TOP10 harboring a pBAD-derivative containing a gene fragment not expressing 
3014-TB (Table 2.4; Section 4.2.2, negative control), called E. coli TOP10. 
- E. coli TOP10 harboring an empty pBAD plasmids (Table 2.3, unpublished by G. 
Mathiesen). 
- E. coli TOP10 harboring a pBAD-derivative containing the Ag85B-ESAT6 antigens, 
lacking the LysM domain (Table 2.3) (called ESAT6 only). 
After co-incubating protein extracts with L. plantarum cells, L. plantarum only were incubated 
with 1 ml PBS, the samples were analyzed by flow cytometry, using anti-ESAT6 and secondary 
FITC labeled antibody HRP-Rabbit Anti-Mouse IgG (referred to as FITC-labeled antibody 
hereafter) (Fig.4.13). 
 
 
Figure 4.13: Flow images using anti-ESAT6, displaying the potential unspecific interactions 
to the cell surface of L. plantarum. The color scheme is shown to the right of the histograms, 
explaining the individual protein extracts bound to living L. plantarum cells, which are 
represented by each colored histogram.  The positive control (green) is the protein extract 
containing 3014-TB bound to the cell surfaces of L plantarum. Note that L. plantarum cells 
charged with ESAT-6 only is the negative sample displaying an unspecific reaction. 
 
L. plantarum charged with 3014-TB has a clear shift towards the right (Fig. 4.13), indicating the 
high amount of FITC-labeled secondary antibodies at the cell surface. The primary antibody 
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anti-ESAT6 recognizes the specific ESAT6-epitopes in 3014-TB, followed by FITC-labeled 
secondary antibody recognizing and binding anti-ESAT6. When cells are analyzed using a laser 
beam, more detected FITC-labeled antibody causes the line representing that sample to shift 
towards the right (after normalizing the number of cells and FITC-detection in the cell sample 
without the added protein extract, the black histogram in Fig. 4.13) (Section 3.23). The only 
negative control that revealed an unspecific interaction with the L. plantarum cells was the 
protein extract containing ESAT6-only (red histogram, Fig. 4.13).  
Flow cytometry is a very sensitive method; therefore, the sample containing ESAT6 only and L. 
plantarum cells (red histogram, Fig. 4.13) was analyzed by western blotting using anti-ESAT6, 
to confirm the unspecific interaction (data not shown). The western blot depicted no unspecific 
interaction, implying that the previously observed unspecific binding (Fig. 4.13) was 
insignificant or too low to be recognized using western blotting. On the other hand, the western 
blot confirmed strong binding of 3014-TB (Appendix, Fig. A1).  
 
4.4.3 3014-TB binds to a broader range of bacteria strains  
3014-TB with the N-terminal Lysine Motif (LysM) domain would theoretically have the ability 
to anchor all bacteria strains containing peptidoglycan. Protein extracts containing 3014-TB 
were, therefore, co-incubated for 1 hour at room temperature with 14 different bacterial strains 
(excluding the already tested L. plantarum WCFS1) harvested in the exponential phase (see 
section 4.4.1 for more details; the bacteria strains are listed in Table 4.1). In this manner, 
detected amounts of 3014-TB displayed on the cell surface of each bacteria strain, analyzed by 
western blotting, could be visually compared using the high intensity bands representing each 
bacterial strain. This would give an indication of the potential alteration of 3014-TB’s ability to 
anchor the different gram positive bacteria (Fig. 4.14). 
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Table 4.1. Bacterial strains used to test binding of 3014-TB 
Lactobacillus spp Other strains 
L. gasseri Streptococcus faecalis 
L. brevis Pediococcous acidolactic 
L. sakei Enterococcus faecium 
L.coryneformis Pediococcus pentisaceus 
L. lactis subspecies lactis (lactis subsp. lactis) Carnobacterium pisicola 
L. rhamnosus GG. Bacillus subtilis 
L. acidophilus E. coli 
 
 
 
 
 
 
Figure 4.14: Western blotting, using anti-His, showing the results after co-incubating 
protein extract containing 3014-TB from E. coli with the 12 bacterial strains indicated in 
each lane. The protein 3014-TB appears in a full-length form (56 kDa) at all cell surfaces, 
excluding the negative control. 3014-TB was also detected as truncated forms (approximately 
20, 30 and 40 kDa) and elongated forms (approximately 80 kDa) in some of the samples. 
Negative control: L. rhamnosus GG cells co-incubated with protein extracts from E. coli TOP10 
cells harboring a pBAD-derivative, not expressing the antigen, Ag85B-ESAT6-DC. 
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3014-TB was displayed on the cell surfaces of all 12 strains of Lactobacillus that were tested, 
both as a full-length protein and truncated/elongated forms, using both anti-ESAT6 (Fig. 4.14, 
excludes L. plantarum) and anti-His (data not shown). The negative control is depicted in Figure 
4.14, and as expected, reveals no positive signals for proteins containing His-tags. E. coli is 
gram-negative and lacks the peptidoglycan outer layer, and was therefore considered to function 
as an additional negative control (Appendix, Fig. A2). 3014-TB was displayed in high amounts 
at the cell surfaces of E. coli, indicated by the high intensity band (Appendix, Figure A2), while 
B. subtilis (as gram-positive) displayed low amount of 3014-TB on the cell surfaces, indicated by 
the low intensity band (Appendix, Fig. A2).  
Fig. 4.14 shows that the amount and degree of fragmentation of anchored 3014-TB varied. A few 
strains were elected for further work, namely B. subtilis, L. gasseri, L. rhamnosus GG and L. 
plantarum WCFS1. L. plantarum was selected because it was the standard strain used in this and 
previous (Øverland 2013) studies; L rhamnosus GG was selected because it is part of the 
Idoform® capsules given to stabilize the gut’s microflora, and were proven to be the 
Lactobacillus strain most stable in bile, in a study by Kõll et al. (2008). L. gasseri was selected 
because it is known to elicit immune activities in humans (Selle & Klaenhammer 2013) and 
modulate dendritic cells in vitro (Luongo et al. 2013). B. subtilis was selected due to the 
promising results used as a delivery vehicle, discovered in a study by Amaguni and Tzipori 
(2012) (described in section 1.3.2). 
The growth phase of the bacteria (stationary or exponential phase) anchoring most 3014-TB to 
the cell surface needed to be determined. Samples from each of the four bacteria strains in both 
stationary and exponential phase were collected and added 11 mg 3014-TB, before incubated for 
1 hour. The amount of 3014-TB on each surface was determined by western blots, using ant-
ESAT6 (Fig. 4.15).  
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Figure 4.15: Western blot, using anti-ESAT6, showing the results after co-incubation of 
protein extract containing 3014-TB with L. plantarum, L. gasseri, L. rhanmosus GG and B.  
subtilis harvested in the exponential (E) phase and stationary (S) phase. 3014-TB is 
displayed as a full-length protein (56 kda) and as truncated forms (30 and 45 kDa) at the cell 
surfaces of the bacterial strains tested, harvested in both stationary- and exponential phase. Note 
that 3014-TB is displayed in higher amounts when incubated using bacterial strains harvested in 
the exponential phase, indicated by the higher intensity band.  
 
The four bacterial strains tested, harvested in the exponential phase, depicted higher amounts of 
3014-TB displayed at their cell surfaces (Fig. 4.15), which is indicated by the higher intensity 
bands. The same was depicted by western blotting using anti-His (data not shown). Flow 
cytometry were used to further confirm that the bacterial strain harvested in their exponential 
phase were optimal when incubated with 3014-TB (Fig. 4.16).  
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Figure 4.16: Flow images of B. subtilis (A), L. plantarum (B), L. GG (C), L. gasseri (D) in 
both stationary and exponential phases, displaying 3014-TB at the cell surfaces. The color 
scheme is shown to the right of the histograms, explaining the individual protein extracts added 
and the cells’ phase when harvested, represented by each colored histogram.  
 
 
Generally, the line shifted furthest to the right was 3014-TB bound to the cells that were 
harvested in the exponential phase (Fig. 4.16, black histogram), which confirms the results 
depicted by western blot (Fig. 4.15); the highest amounts of 3014-TB was observed when cells 
harvested in the exponential phase were used.  
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4.4.4. 2162-TB anchored to the cell surface of Bacillus subtilis and Lactobacillus spp. 
Following the discoveries of 3014-TB attached to the bacterial strains used (see section 4.4.1 and 
4.4.3), protein extracts containing 2162-TB from E. coli were co-incubated with L. plantarum, L. 
gasseri, L. rhamnosus GG and B. subtilis, harvested in exponential- and stationary phase. The 
protein extracts containing 2162-TB were incubated for 1 hour at room temperature, with 
bacterial strains, before analyzed by western blotting, using anti-His (Fig. 4.17).  
 
 
 
 
 
 
Figure 4.17: Western blot, using anti-His, showing the results of co-incubated protein 
extracts containing 2162-TB with the indicated bacterial strains, harvested in the 
stationary- (S) and exponential (E) phase. The bacterial strains are indicated above the lanes. 
2162-TB is displayed as a full-length protein of 60 kDa, in almost equally amounts on the cell 
surfaces of the bacterial cells harvested in both stationary and exponential phase.  
 
2162-TB displayed on the cell surfaces of the four strains were depicted in Fig. 4.17, the same 
degree of anchored 2162-TB was observed for cells harvested in both stationary- and exponential 
phase. After analyzing the samples by flow cytometry, using anti-ESAT6 (data not shown), the 
20 
30 
40 
50 
60 
80 
kDa 
100 
60 kDa 
RESULTS 
91 
 
protein 2162-TB was observed to anchor B. subtilis cells, harvested in the stationary- and 
exponential phase, in the same degree. For L. plantarum, L. GG and L. gasseri the highest degree 
of anchored 2162-TB was observed when cells were harvested in the stationary phase (data not 
shown). 
In all further work, 2162-TB and 3014-TB were anchored to cells harvested in the exponential 
phase to simplify the comparison of the results obtained for both proteins.  
 
4.5 Effect of low pH and bile on 3014-TB and 2162-TB 
Proteins displayed on delivery vehicles, which are orally administrated, need to resist 
degradation in low pH values and high bile concentrations (Marteau et al. 1997). In addition, 
3014-TB and 2162-TB anchored to cell surfaces of bacteria must resist longer storing times, so 
the vaccine can be manufactured and transported between countries all over the world without 
losing effect. 
 
4.5.1 3014-TB and 2162-TB after freeze drying and storage 
The protein extracts containing 2162-TB or 3014-TB were stored at 4⁰C. After 3 weeks of 
storage, neither 2162-TB nor 3014-TB was observed at the cell surfaces following co-incubation 
(data not shown). To elongate the stability of 3014-TB and 2162-TB during storage, the proteins 
were tried stored while attached to the bacterial cell surfaces, using freeze drying (see section 
3.26). Due to the distress caused by freeze drying on cells and proteins, a freeze dry medium 
(composed of skimmed milk and fructose) were added before bacteria cells charged with 2162-
TB or 3014-TB were freeze dried overnight. Following the freeze drying, the samples were 
stored in the dark, at room temperature for 1 week. The freeze dried bacteria cells displaying the 
3014-TB or 2162-TB were kept stable during 1 week of storage (Fig. 4.18). 
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Figure 4.18: Flow cytometry to analyze the effect of freeze-drying and storage on L. 
plantarum displaying 3014-TB (left) and 2162-TB (right). The color scheme is shown to the 
right of the histograms. The control samples (green and blue) were analyzed after freeze drying 
and 1 week of storage. 
 
The histogram representing L. plantarum displaying 3014-TB or 2162-TB that were stored for 1 
week (Fig. 4.18, black histogram), depicts the same shift as for L. plantarum displaying 3014-TB 
or 2162-TB without storage (Fig. 4.18, red histogram). This indicated that the charged L. 
plantarum was stable after 1 week of storage. L. plantarum charged with 3014-TB were 
additionally stored for 3 months after freeze drying; to observe the increased storing time’s effect 
on the stability of L. plantarum displaying 3014-TB (Fig. 4.19). 
 
  
Figure 4.19: Flow images of L. plantarum displaying 3014-TB after freeze drying and 3 
months of storage. The color scheme is shown to the right of the histograms. The control 
samples (green and blue) were analyzed after freeze drying and 3 months of storage. 
RESULTS 
93 
 
The negative samples stored for 3 months (green and blue histogram, Fig. 4.19), not displaying 
ESAT6-epitopes, were almost shifted equally towards the right as the L. plantarum cells charged 
with 3014-TB (red and black histograms, Fig. 4.19). This tendency was not observed for the 
analyzed negative samples stored for 1 week (green and blue histogram, Fig.4.18), which 
indicates that the freeze drying medium, when stored with samples for longer time periods, 
probably results in an unspecific interaction with the primary antibody anti-ESAT6. The data 
indicate that L. plantarum cells displaying 3014-TB have the ability to be stored using freeze 
drying, but, for now, only in shorter time spans.    
 
4.5.2 L. plantarum cells displaying 3014-TB or 2162-TB, incubated in low pH values 
Before the vaccine reaches the mucosal surfaces in the intestine, the vaccine has to resist the low 
pH values found in the stomach, while the proteins displayed at the cell surfaces need to remain 
intact (Marteau et al. 1997). 
The time needed to resist low pH depends on the food ingested. For example, the pH 
composition in a human stomach after ingesting a yoghurt starts at pH = 5 (20 min), then 
lowered to pH = 4 (40 min), before pH = 2 is kept for 60 minutes. Finally the pH value 1.8 is 
kept for more than 80 min (Marteau et al. 1997). According to this, the L. plantarum cells 
displaying 3014-TB or 2162-TB were incubated in pH values ranging from 1.5–6.5 for 2 hours at 
37⁰C. After incubation, the samples were washed 3x, using 1 ml of PBS (as described in section 
3.21, step 5–7) and stained following the pre-stained protocol (section 3.23) for analyzing by 
flow cytometry, using anti-ESAT6 (Fig. 4.20). 
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Figure 4.20: Flow images of L. plantarum displaying 3014-TB (left) or 2162-TB (right), 
incubated for 2 hours in a broad range of pH values. The color scheme is shown to the right 
of the histograms. L. plantarum displaying 3014-TB/2162-TB was incubated in pH regulated 
(indicated by the color scheme) MRS medium. The negative control (black) is L. plantarum 
charged with the protein extract of E. coli TOP10 (harboring a pBAD-derivative, not expressing 
the antigen Ag85B-ESAT6-DC, incubated in MRS medium, not pH-regulated. 
 
L. plantarum displaying either 2162-TB or 3014-TB was stable after incubation in pH-regulated 
(from 1.5–6.5) MRS medium (Fig. 4.20). The four bacteria strain charged with 2162-TB or 
3014-TB, after freeze dried and stored for 1 week, were incubated in pH-regulated MRS medium 
(data not shown), revealing the same stability as for the samples observed in Fig. 4. 20.  
 
4.5.3 L. plantarum cells displaying 3014-TB or 2162-TB, incubated in bile 
After resisting the low pH values in the stomach (see section 4.5.2), the vaccine has to resist bile 
concentrations reaching 4% in the small intestine. The bile concentrations vary from 0.8–4% 
after ingesting a meal (Marteau et al. 1997), just as the pH values vary. Therefore, L. plantarum 
charged with 3014-TB/2162-TB, were incubated for 1 hour in bile concentrations of 2% at 37⁰C, 
before analysis by flow cytometry (Fig. 4.21). 
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Figure 4.21: Flow images of L. plantarum displaying either 3014-TB or 2162-TB, incubated 
in 2% bile for 1 hour, at 37⁰C. The color scheme is shown to the right of the histograms. L. 
plantarum displaying 3014-TB/2162-TB was incubated in MRS medium containing 2% bile as 
the final concentration. The negative control (black) is L. plantarum charged with protein extract 
of E. coli TOP10 (harboring a pBAD-derivative, not expressing the antigen Ag85B-ESAT6-DC), 
incubated in MRS medium containing 2% bile as the final concentration. 
 
The results indicate that the L. plantarum charged with 3014-TB (Fig. 4.21, blue histogram) 
resists incubation in 2% bile better than L. plantarum charged with 2162-TB (Fig. 4.21, red 
histogram), but there are uncertainties since the negative control reveals an unspecific interaction 
with the anti-ESAT6. Pellets treated with bile become strongly colored, which potentially are 
misinterpreted as positive results, analyzed by flow cytometry. This was also the case analyzing 
with western blots (data not shown).  
After incubating the negative control in MRS medium containing 4% bile as the final 
concentration, the unspecific interaction with anti-ESAT6 increased, causing the histogram 
representing the negative control to shift equally towards the right as histograms representing the 
samples including 3014-TB and 2162-TB. The anchored 3014-TB and 2162-TB to L. plantarum 
cells’ ability to resist incubation in bile must be analyzed further using another system, not 
affected by the color given after bile incubation.  
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4.6 Expression of Lp_3014-TB and Lp_2162-TB in Lactobacillus plantarum 
In studies done by Tjåland (2011) and Øverland (2013), the proteins containing tuberculosis 
(TB) antigen were expressed in L. plantarum, and displayed on the cells’ own surface (self-
expressing L. plantarum). The approach in the present study has taken a different angle, since 
heterologously produced proteins were anchored to non-GMO L. plantarum, which does not 
express these proteins. Both studies depend on using L. plantarum as a delivery vehicle for 
displaying proteins containing TB-antigens, and were therefore compared; potentially 
determining the better approach for anchoring proteins to delivery vehicles.  
 
4.6.1  The construction of Lp_2162-TB and Lp_3014-TB 
The gene fragments of 2162-TB and 3014-TB were altered to include the original signal 
sequence placed at the N-terminus of the proteins. The new fragments were ligated into NdeI and 
EcoRI digested pSIP plasmids, producing the final fragments Lp_2162-TB and Lp_3014-TB 
(Fig.4.22), which uses the vector system of L. plantarum (Sørvig et al. 2005) to make self-
expression possible.  
 
 
Figure 4.22: Schematic overviwe of the final constructs of Lp_3014-TB and Lp_2162-TB 
respectively, cloned into the pSIP system. In these constructs, the signal sequence (leading the 
expressed proteins out of the cell) is located at the N-terminus. The restriction sites used to digest 
the pSIP-plasmids are visualized.  
 
The final constructs (Fig. 4.22) were transformed into E. coli TOP10 competent cells, the 
plasmids were isolated and purified before transformation to electrocompetent L. plantarum. 
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4.6.2  Lp_3014-TB and Lp_2162-TB displayed at Lactobacillus  plantarum surfaces  
The production of Lp_3014-TB and Lp_2162-TB in L. plantarum cultures was detected using 
western blot analysis of cell extracts obtained  after cell-disruption with glass beads (data not 
shown), using cells harvested 2 hours after induction with 25 ng inducing peptide SppIP (see 
section 3.24 and 3.25). L. plantarum cultures were induced before they reached OD600= 0.33, and 
after induced, the growth of L. plantarum cultures were monitored in the following 5 hours (a 
total of 8 hours; Appendix, Fig. A5). L. plantarum expressing the proteins, Lp_2162-TB or 
Lp_3014-TB, were revealed to have a slower growth rate than the L. plantarum cells not 
harboring a pSIP-derivative.  
The extracellular attached proteins on L. plantarum’s own surface were verified with flow 
cytometry; 2 and 5 hours after induced and treated with lysozyme. Lp_2162-TB was embedded 
in the structure after 2 and 5 hours, where lysozyme treatment was used to visualized the proteins 
at the cell surface (Appendix, Fig. A6). The highest amount of detected proteins of Lp_2162-TB 
on the cell surface was after 5 hours incubation and lysozyme treatment. Lp_3014-TB was partly 
displayed at the cell surface after incubated for 2 and 5 hours, and, Lp_3014-TB was completely 
revealed after lysozyme treatment after incubated for 2 hours (Appendix, Fig. A7). However, 
lysozyme treatment after incubated for 5 hours (Appendix, Fig. A7), revealed a histogram with 
two separated tops; suggesting that the already displayed Lp_3014-TB were degraded after 
lysozyme treatment, while the previously embedded proteins of Lp_3014-TB became exposed. 
The degree of displayed proteins of Lp_3014-TB on the cell surface was almost similar for 2 and 
5 hours, but even when split in two, the top depicting the displaying Lp_3014-TB proteins after 5 
hours incubation was shifted furthest to the right.  
The amount of proteins detected on cell surfaces of self-expressing L. plantarum, never exceeded 
the amount of proteins detected on L. plantarum displaying 3014-TB or 2162-TB (Fig. 4.23).  
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Figure 4.23: Flow images comparing L. plantarum expressing and displaying Lp_2162-TB 
(right) or Lp_3014-TB (left), to L. plantarum charged with 2162-TB or 3014-TB, 
respectively. The color scheme is shown to the right of the histograms, explaining the individual 
samples represented by each colored histogram. The negative sample was L. plantarum cells not 
harboring a pSIP-derivative, induced with SppSIP and incubated for 5 hours. 3014-TB and 2162-
TB were incubated for 1 hour at room temperature with L. plantarum cells harvested in 
exponential phase.
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5. DISCUSSION 
 
5.1 Intracellular production of 3014-TB and 2162-TB in Escherichia coli 
The display of proteins on lactic acid bacteria (LAB) leading to a vaccine is a well-known 
approach (Daniel et al. 2011; Wells 2010; Wells & Mercenier 2008), depending on the use of 
GMO bacteria. The novelty of the present study lies in developing methods to non-covalently 
anchor heterologous proteins to LAB, to create a non-genetically modified organism (non-GMO) 
displaying a vaccine (Bosma et al. 2006). For a heterologous protein to anchor gram positive 
bacteria, the proteins need to be produced in large quantities through easy cloning and bacterial 
culturing. E. coli is well adapted for this purpose and was therefore chosen for this study. The two 
antigens from Mycobacterium tuberculosis (Mtb) fused together to the Ag85B-ESAT6-DC fusion 
protein, have been explored in previous studies based on using GMO-LAB, and have shown 
promising results (Tjåland 2011; Øverland 2013). 
The proteins were intracellularly expressed through the inducible pBAD-vector system, which 
uses the araBAD promoter to enhance expression of the protein of interest. After optimizing the 
expression-conditions, 3014-TB and 2162-TB were successfully produced intracellularly in E. 
coli cultures. The optimal conditions were grown at 18⁰C, induction with 0.02% arabinose and 
incubation for 12 hours after induction. E. coli, which is a typical mesophilic bacterial strain 
(Broweze et al. 1978) grows in temperatures from 15–40⁰C, and both growth rate and the rate of 
translation vary within this temperature interval. The lowest growth temperature for E. coli is 
proven to be 7.8⁰C (Shaw et al. 1971), and at such low temperatures protein synthesis will be 
reduced to a minimum, or completely stop (Jones et al. 1987). A temperature of 18⁰C, which was 
used in this study, causes a slow growth rate for E. coli; which was considered as an advantage, 
because the proteins, 3014-TB and 2162-TB, would be given time to fold properly, into 
potentially soluble proteins. E. coli did still express proteins at this temperature, and did indeed 
produce soluble 3014-TB and 2162-TB. E. coli cultures grown under these conditions produced 
full-length 3014-TB (56 kDa) and 2162-TB (60 kDa), as confirmed with western blots. 
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5.2 Purifying 3014-TB and 2162-TB from Escherichia coli protein extract 
To obtain optimal samples for subsequent anchoring to LAB, attempts were made to purify His-
tagged 3014-TB and 2162-TB from cell extracts of E. coli strains. The use of a His-tag (7 
Histidines), attached either at the N- or C-terminus of the protein have been explored prior to this 
work, as an affinity tag to purify particular proteins (Lee et al. 2014; Ma et al. 2014).  
His-tagged proteins were released from the E. coli interior using sonication, which breaks the 
cells using intervallic sound waves, resulting in protein extracts. The challenge of continuously 
discover the protein 3014-TB in the flow through were met in the attempt to purify the protein 
from the resulting protein extracts using a Ni-NTA column. This challenge was assumed to arise 
from an embedded His-tag in 3014-TB, since the problems remained even after optimizing the 
Buffer composition; buffer A were optimize to contain 1 M Tris HCl pH 7.4, excluding imidazole 
completely, preventing competition for 3014-TB to bind the Ni-NTA column.  Buffer B 
contained 1 M Tris HCl pH 7.4 and 500 mM imidazole, causing any potential proteins bound to 
the Ni-NTA column to be released into the eluate.  
By denaturing the protein 3014-TB in 8 M urea before purified, using the buffer compositions 
described (included the denaturant, 8 M urea); 3014-TB was depicted in the eluate in a higher 
detectable amount than in the flow through. Following the purification of 3014-TB, the protein 
was tried refolded by the removal of denaturants, either gradually using refolding solution, or 
fast, using dialysis. The gradual removal of denaturants caused aggregation of proteins, while the 
fast removal resulted in a soluble 3014-TB which unfortunately did not have the ability to anchor 
the cell wall of L. plantarum.  
Hopefully, by elongating the distance between the His-tag and the antigens (Ag85B-ESAT6-DC), 
the His-tag would avoid being embedded in the protein structure. The two constructs included in 
this study, 3014-TB and 2162-TB, differed in the numbers of LysM domains in their anchoring 
domains, where 3014 contained one LysM domain while 2162 contained two LysM domains 
(Fig. 1.3 and 5.1). Expanding the anchoring domain from one domain (3014) to include two 
domains (2162) increased the length of the protein fragment between the His-tag and the antigens 
by 1.5-fold. To avoid the embedded His-tag, two 2162-TB candidates were made varying in the 
last PST linker region (Figure 5.1). 
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Figure 5.1: Illustration of a protein containing 2 LysM domains, separated by PST linker 
regions. This protein is built similarly to 2162-TB, with the two LysM domains separated by a 
PST linker region. In contrast, 3014-TB only contains one LysM domain, followed by a PST 
linker region, separating the LysM domain from the antigens. Following the 2
nd
 LysM domain in 
2162-TB, is an additional PST linker region, separating the LysM domain and the antigens; the 
number of residues included in the two 2162-TB candidates is given at the bottom of the figure. 
This figure is an alteration of (Ohnuma et al. 2007). 
 
The natural Lp_2162 gene encodes a double LysM domain (Fig. 1.3 and 5.1), with a long PST 
linker region following the second LysM domain. The two constructs were made by ending the 
PST linker region at two natural points, resulting in a longer fragment (2162_L) and a shorter 
fragment (2162_S) (Fig. 5.1). The PST linker region is increased by 223 amino acid residues, 
from 2162-TB_S to 2162-TB_L (Fig. 5.1), which also equally increases the length between the 
His-tag and the antigens.  
2162-TB_S and 2162-TB_L were tried purified in the optimal buffer compositions described, 
revealing 2162-TB_S in a full-length form (60 kDa) and a punctuated form (35 kDa), while 
2162-TB_L were only depicted in a punctuated form (35 kDa). The punctuated form of 2162-
TB_L implies that the longer PST linker region was exposed to cleavage by proteases. In addition 
to being cleaved, 2162-TB_L was not depicted in the eluate, leaving 2162-TB_S as the only 
candidate of 2162-TB to be depicted in the eluate, and was therefore the candidate of 2162-TB 
included in the further experiments (referred to as 2162-TB hereafter).  
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While 3014-TB and 2162-TB eventually could be produced as soluble proteins in E. coli, 3014-
TB could unfortunately not be purified. Whereas 2162-TB could be purified, the resulting 
purified proteins were not detected at the surfaces of L. plantarum cells, which could be 
explained by the low yield of purified 2162-TB (1.67 mg/ml). Therefore, 3014-TB and 2162-TB 
were administrated as total protein extracts to anchor the surfaces of gram positive bacteria. 
There are disadvantages following the administration of protein extracts rather than purified 
proteins, one being the protein extracts’ additional substances, which potentially could bind to the 
cell surfaces yielding, unknown effects by altering the cell surface. The use of protein extracts 
containing 3014-TB and 2162-TB, rather than the purified proteins, also has the disadvantage that 
administrated antigen concentration is unknown and hard to control. If the elicited immune 
response depends on the concentration of antigens administrated, and there is a threshold needed 
to elicit an immune response (Wells & Mercenier 2008), the protein concentration being 
unknown and uncontrollable may cause problems. 
 
 
5.3 Anchoring 3014-TB and 2162-TB to the cell surface  
The use of LysM domains to non-covalently anchor heterologous proteins to the cell wall of gram 
positive bacteria is an increasingly popular field in the development of vaccines (Bosma et al. 
2006; van Roosmalen et al. 2006; Xu et al. 2011), because LysM domains are known to bind the 
varying and complex structure of peptidoglycan, chitin (Ghuysen 1986; Wong et al. 2013) and 
potentially teichoic acid (Navarre & Schneewind 1999). Due to the LysM domains abilities to 
anchor this cell wall structures, 3014-TB and 2162-TB were expected to bind to the cell surfaces 
of a broad range of gram positive bacteria.  
After co-incubating gram positive bacterial cells with protein extracts for 1 hour, the western 
blots revealed that the vaccine-constructs, 3014-TB and 2162-TB, were bound to all the 14 gram-
positives tested in this study. 3014-TB and 2162-TB were also observed at the gram-negative E. 
coli (the strains are listed in Table 4.1). Surprisingly, 3014-TB and 2162-TB were found to 
anchor less efficiently to B. subtilis (Appendix, Fig. A3). Only a small amount of 3014-TB was 
observed at the surfaces of B. subtilis compared to similar Lactobacillus spp used in this, and 
previous studies (Steen et al. 2003). So far, there is no explanation for why LysM-containing 
proteins anchor less efficiently to the cell wall of B. subtilis, but LysM-containing proteins have 
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been discovered to anchor B. subtilis at specific locations, in a ring-like manner, surrounded by 
areas rich in lipoteichoic acid, yielding visually lower densities of displayed LysM-contained 
proteins in contrast to Lactobacillus spp (Steen et al. 2003). LysM domains are thought to bind 
the NAG monomers of the peptidoglycan structure, which interestingly is the only similarity 
discovered between peptidoglycan and chitin (Visweswaran et al. 2012). If the structure that 
LysM domain recognizes could be determined, this information could be used to potentially 
specify the LysM domains’ binding affinity towards the type of bacterial strain used.  
3014-TB and 2162-TB, due to the LysM anchor, were detected to anchor a broad range of gram 
positive bacteria, including the gram negative bacteria, E. coli, using western blotting and flow 
cytometry.  Both western blotting and flow cytometry uses immunostaining, which exploits the 
antigen-antibody-interaction to detect (e.g.) a protein of interest, and is considered as reliable 
methods to verify the presence of a particular protein (Lea 2006). If the confocal microscopy 
were to be included as a method to further investigate 3014-TB and 2162-TB on the cell surfaces, 
the distribution of the proteins on the cell surfaces could be determined as well. Therefore, 
confocal microscopy should have been included in this work.  
Western blotting used to detect particular proteins is considered to be semi-quantitative, because 
the amount of proteins in the sample is indicated by the band intensities. Flow cytometry, on the 
other hand, discriminates between the individual cells in the analyzed sample, yielding 
quantitative results of the sampled cells (Lea 2006). Though quantitative, the concentrations of 
3014-TB and 2162-TB displayed at the cell surfaces should be thoroughly measured using e.g. 
Bradford method. The concentration of 3014-TB and 2162-TB were not determined in this study, 
mainly due to the use of total protein extracts when co-incubating with bacteria. Determining the 
protein concentration of the particular protein and avoid the interfering protein, are challenging 
(Rosenberg 2005), and therefore, 3014-TB and 2162-TB should be purified using another affinity 
tag, before determining the concentration of the purified protein.  
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5.4 Comparing the potential of 3014-TB and 2162-TB  to bind to cell surfaces 
of L. plantarum  
An orally administrated vaccine has to resist harsh environments in the gastrointestinal tract 
(GIT). Antigens displayed at the cells surface are thought to be more immunogenic compared to 
cytoplasmic antigens (Wells & Mercenier 2008). However, displayed antigens are more exposed 
for degradation during their passage through the digestive tract, and therefore, is the choice of 
lactic acid bacteria as delivery vehicle considered to be important, due to their resistance against 
these harsh GIT environments (Wells & Mercenier 2008). L. gasseri is known to survive low pH 
values (2.5), L. plantarum is more stable at these pH values, while L. rhamnosus GG is more 
tolerant against bile compared to L. gasseri and L. plantarum (Kõll et al. 2008). For the delivery 
vehicles charged with 3014-TB or 2162-TB to elicit immune responses, the proteins 3014-TB 
and 2162-TB has to stay on the cell surfaces through the GIT passage; facing lower pH values, as 
1.8, and bile concentrations ranging from 2–4% (Marteau et al. 1997).  
In this study, L. plantarum cells charged with 3014-TB or 2162-TB were incubated in pH values 
ranging from 1.5–6.5, and bile concentrations ranging from 2–4 %. The amount of 3014-TB and 
2162-TB displayed at the cell surfaces after pH-incubation were compared to the L. plantarum 
cells displaying 3014-TB or 2162-TB not incubated in pH, using flow cytometry. Flow cytometry 
gives a more qualified quantitative guess than western blotting. The histograms representing the 
L. plantarum cells displaying 3014-TB and 2162-TB incubated in low pH values revealed almost 
the same shift compared to the histogram representing the untreated protein-displaying cells, 
which indicates that 3014-TB and 2162-TB hardly were affected by the low pH values. The 
effect following 2% bile administration indicates that 3014-TB resists bile incubation better than 
2162-TB. However, the negative control (cells not displaying 3014-TB or 2162-TB) represented 
by a histogram revealed, after incubated in bile, a shift towards the right which implied an 
unspecific interaction. After increasing the bile concentration from 2% to 4 %, the histogram 
representing the negative control were observed to shift equally to the right as the histogram 
representing the samples containing 3014-TB and 2162-TB. The cell pellet following bile 
administration is brightly colored, which probably caused this shift in the histogram representing 
the negative sample. Other methods (not affected by the colored cell pellet) should therefore be 
included before the final conclusions are drawn.   
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L. plantarum cells charged with 3014-TB and 2162-TB, analyzed by flow cytometry, revealed 
the potential to stay stable during storage for one week, after freeze drying. The histogram that 
represented cells displaying 3014-TB or 2162-TB were, after storage, observed to shift equally 
towards the right as the histograms representing the cells displaying 3014-TB and 2162-TB not 
stored before analyzed. Freeze drying causes distress on cells and proteins, and the cells and 
proteins are protected by adding a freeze dry medium to the sample. The optimal effect of the 
freeze dry medium on the particular bacterial strain or protein used, depends on the chosen 
combination of the freeze drying medium’s components (Leslie et al. 1995). Because the L. 
plantarum cells displaying 3014-TB and 2162-TB were observed to be stable for only one week, 
the freeze dry medium targeting the particular combination of bacterial strains and proteins used 
in this work, should be further optimized. 
Finally, data obtained from this study reveals that both 3014-TB and 2162-TB anchors to the cell 
surfaces of gram positive bacteria. Additionally, the cells displaying 3014-TB or 2162-TB have 
the ability to resist degradation during incubation at low pH and possibly bile, and can be stored 
in a freeze-dried form for at least 1 week. Future work should account for the challenges facing 
the limiting time of storage, by changing the component of the freeze dry medium to result in the 
optimal combination, yielding the best protection for L. plantarum cells displaying 3014-TB or 
2162-TB. The protein-displaying cells’ ability to resist degradation in bile needs to be 
determined, using a method that will not be affected by the colored cell-pellet. The 3014-TB or 
2162-TB displayed L. plantarum cells should preferably be tested in environments including 
more than one factor at a time; e.g. expose the displayed cells to the low pH values and a 
protease-activity subsequent to the environments detected in the stomach. 
 
 
5.5 Comparisons of the constructs 2162-TB and 3014-TB  
Some examples in literature reveal the need for larger clusters of LysM domains, N- or C- 
terminally located in proteins, in order to obtain their optimal binding capacity (Bateman & 
Bycroft 2000; Petutschnig et al. 2010; Wong et al. 2013). Two LysM containing anchoring 
domains were therefor tested for the antigen-containing protein used in this study, which 
hopefully would help determining the better anchor: 2162 (two LysM domains) or 3014 (one 
lysM domain) (Figure 1.3).  
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Co-incubation of 3014-TB and L. plantarum, L. rhamnosus GG, L. gasseri or B. subtilis, revealed 
surface exposed proteins using flow cytometry and western blotting. The same was observed 
upon co-incubation with 2162-TB. The amount of displayed proteins was visually estimated by 
comparing the band intensities in western blots or the histograms representing the samples shifts 
towards the right in flow cytometri. Comparing the amount of displayed 3014-TB and 2162-TB 
at the cells surfaces revealed an inconsistency when comparing all the individual experiments 
conducted in this study (data not shown). This ambiguity could have been reduced by closely 
monitoring the concentration of the total protein extracts administrated before co-incubating the 
protein extracts with bacterial cells. The protein extracts containing 3014-TB and 2162-TB were 
usually stored in 4⁰C before incubated with bacterial cells; the ambiguity could have been 
reduced by continuously avoid storing the protein extracts before administrated.   
Incubating cells displaying 3014-TB or 2162-TB in low pH values revealed an almost equal shift 
of the histograms representing each of the protein samples. In contrast, histograms representing 
cells displaying 3014-TB were usually shifted further to the right than the histograms 
representing 2162-TB charged cells when faced with bile. A possible explanation is that the 
smaller 3014-TB (56 kDa) is more protected from the surrounding environment, than the larger 
(60 kDa) and potentially more exposed 2162-TB. This could in an immunologically perspective, 
cause a disadvantage. Antigens protected in the folded protein structure could be hidden from 
interacting with immune cells to elicit an immune response.  
So far, the data indicates that the cells displaying 3014-TB have the slighter advantage over cells 
displaying 2162-TB, regarding the stability when incubated in bile. In future aspects, the effect 
following bile incubation on the cells displaying either 3014-TB or 2162-TB should be 
determined using another method. The results for the protein amounts displayed at the cells 
surface was ambiguous, thus, no conclusions can be made. A final conclusion could be drawn 
after determining the potential elicited immune response.  
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5.6 Comparing L. plantarum cells charged with Lp_3014-TB or Lp_2162-TB  
to the cells charged with 3014-TB or 2162-TB 
Prior to this study, L. plantarum had been used to express and expose the Ag85B-ESAT6 fusion 
antigen at its own surface, giving the disadvantage of resulting in a GMO vaccine (Tjåland 2011; 
Øverland 2013). The use of GMO is controversial (see section 1.6), and a non-GMO vaccine 
would be received better in many countries when introduced.  
By altering 3014-TB and 2162-TB, the proteins were intracellularly produced in L. plantarum 
and displayed at the cell surface. To accomplish this, the signal peptide sequences present in 
Lp_2162 and Lp_3014 that were removed in the constructs discussed so far, were kept, in order 
for the fusion proteins to be secreted from the cells. The new Lp_3014-TB and Lp_2162-TB 
fragments were cloned into the L. plantarum pSIP inducible vector system. Images retrieved from 
flow cytometry of L. plantarum expressing Lp_2162-TB, suggested that the protein was 
displayed (Appendix, Fig. A6). The protein was only detected after lysozyme treatment, 
indicating that it was deeply embedded in the cell wall. Expressed Lp_3014-TB proteins, on the 
other hand, were suggested to be partly embedded in the cell wall of L plantarum (Appendix, Fig. 
A7), due to the split histogram representing L. plantarum cells expressing Lp_3014-TB after 
incubation for 5 hours and lysozyme treatment. Which implies deeply embedded Lp_3014-TB in 
the cell wall structure that was detected after lysozyme treatment, while the Lp_3014-TB that 
were displayed at the cell surface from the beginning, were degraded after lysozyme treatment 
(Fig. A7). Other embedded protein containing TB-antigens at the L. plantarum surfaces have 
elicited promising immune responses in mice (Øverland 2013), suggesting that embedded 
Lp_3014-TB and Lp_2162-TB on L. plantarum could potentially elicit immune responses as 
well.  
Finally, expressed Lp_3014-TB or Lp_2162-TB were detected at the surfaces of L. plantarum 
cells after incubating for 5 hours and lysozyme treatment, followed by analyzing the samples by 
flow cytometry. The histogram representing L. plantarum cells displaying Lp_3014-TB or 
Lp_2162-TB were not shifted as far to the right as the histograms representing the L. plantarum 
cells displaying 3014-TB and 2162-TB, implying that an higher amount of antigens (Ag85B-
ESAT6-DC) were presence at the cells displaying 3014-TB and 2162-TB. Hopefully, higher 
concentrations of displayed antigens could elicit stronger and longer-lasting immune responses. 
DISCUSSION 
108 
 
5.7 Concluding remarks and future perspectives 
Hopefully, results from this study will help future studies towards the development of a non-
GMO vaccine against tuberculosis (TB). The promising antigens (Ag85B-ESAT6) have 
successfully been expressed intracellularly in E. coli and the heterologous proteins could be 
anchored to 14 different strains of gram-positive bacteria, through their peptidoglycan binding 
domain (LysM domain). The bacterial cells displaying the heterologous proteins provide an easy 
and low cost vaccine manufacturing method, and have shown resistance against stomach- and 
intestinal-like environments. The vaccine was resistant against low pH values (1.5–6.5) and 
possibly bile conditions (2%), and has the ability to be stored for at least 1 week. Future work 
should include determining the potential elicited immune responses, and address the main 
problems discovered during this work: the use of purified proteins as opposed to cell extracts and 
increasing storage stability. 
Use of protein extracts rather than the purified protein may cause unknown side effects when 
administrated (see section 5.2). To avoid this, 3014-TB and 2162-TB should be purified, 
potentially using another small affinity tag. A small affinity tag has the advantage to fuse directly 
to the antigens in the proteins without altering the tertiary structures, and do not need to be 
removed after purification (Terpe 2003). If the small affinity tags do not result in purified 
proteins, the tag could be replaced within the protein, e.g. internally, or at the C- or N-terminus. 
The proteins could be purified using larger fused peptides, but this is a rather expensive and 
complicated protocol, therefore, small-affinity tags should be considered firstly. The choice of 
any tag (large or small) to be used to purify proteins depends on the protein-type used, the 
expression system of the protein and the proteins’ application afterwards (Terpe 2003).  
Current vaccines are usually manufactured in one country and then exported to the country where 
they are to be administrated. Marketed vaccines therefor need the ability to resist longer storing 
periods without degrading before being administrated. Degraded vaccines would be more 
vulnerable when facing the harsh environment found in the GIT, and possibly lose the potential 
to elicit an immune response, e.g. as a result of proteolytic attack in the stomach. Hopefully, by 
altering the freeze dry mediums’ composition to result in an optimal protection towards the cells 
charged with 3014-TB and 2162-TB, the protein-charged cells’ stability could exceed 1 week of 
storage and potentially after administrated.  
DISCUSSION 
109 
 
Before the potential vaccines generated in this study can reach mouse trials, the ability for L. 
plantarum cells displaying 3014-TB and 2162-TB to elicit a potential immune response needs to 
be determined. Previous studies have revealed detectable immune responses against the antigens 
used (Ag85B-ESAT6) (Dietrich et al. 2006; Doherty et al. 2004) also when displayed on L. 
plantarum through self-expression (Øverland 2013). Thus, the potential to elicit an immune 
response is defiantly present. Furthermore, it has been shown that the 12-mer specific DC-
targeting sequence attached C-terminally to the proteins used in this study stimulates the 
immunogenic effects of the antigen coupled to it (Mohamadzadeh et al. 2009; Øverland 2013). 
All in all, the cells charged with either 2162-TB or 3014-TB have the potential to elicit an 
immune response through the targeting of DC. Which, finally, would give the possibility to 
determine the better anchor-domain for the heterologous protein used in this study. 
The future goal is to produce a vaccine against tuberculosis, which results in a better and longer-
lasting immune response than the BCG-vaccine. Probably, both GMO and non-GMO routes will 
be developed. The present study provides a first step towards a non-GMO vaccine, which may 
provide a favorable choice in the future.  
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Figure A1: Western blot, using ESAT6, showing result of the optimal production of protein 
extracts containing 3014-TB, from E coli. 3014-TB was grown at 18⁰C, induced with 0.02% 
arabinose, followed by incubation for 12 hours. 3014-TB is shown as a full-length protein 
(56kDa). Negative control; protein extracts of E. coli, harboring a pBAD-derivative lacking the 
antigen (Ag85B-ESAT6-DC), grown in the same manner as the 3014-TB protein. 
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Figure A2: SDS-gels of cell extracts from cells harboring 2162-TB_S and 2162-TB_L, 
grown at 18⁰C, induced with 0.02% arabinose and harvested after 12 hours of incubation. 
The expected size of the overexpressed protein 2162-TB_S is 60 kDa, and the band 
corresponding to this size is indeed observed in the sample containing 2162-TB_S, while the 
expected size of the protein 2162-TB_L is 67 kDa, a band approximate to this size is observed in 
the flow through.  
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Figure A3: Western blot, using anti-His, depicting the resulting supernatant 1–4 and cell 
pellet after 60 min of co-incubation of protein extracts containing 3014-TB with L. 
plantarum cells.  3014-TB bound to living L. plantarum cells harvested in the exponential phase 
is shown, while 3014-TB is not observed in any of the four supernatants.  
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Figure A4: Western blot, using anti-His, showing the result following the co-incubation for 
60 min, of E. coli and B. subtilis cells with protein extracts containing soluble 3014-TB. After 
60 min co-incubation, 3014-TB was displayed at the cell surfaces of E. coli and the B. subtilis, 
both harvested in the exponential phase. The negative controls are protein extracts of E. coli 
harboring pBAD-derivative lacking the antigen Ag85B-ESAT6-DC, co-incubated with both E. 
coli and B. subtilis cells, harvested in their exponential phase.  
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Figure A5: Schematic overview of the average growth for L. plantarum cells harboring 
different plasmids. The color scheme is listed to the right. All three were induced with inducer 
peptide 25 ng SppIP after approximately 3 hours. L. plantarum cells not harboring pSIP-
derivative have a higher growth rate than the L. plantarum cells harboring the pSIP-derivatives, 
after induced with the inducer peptide. The standard deviation for each measured OD600 is given.  
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Figure A6: Flow images revealing Lp_2162-TB displayed at the surfaces of L. plantarum 
cells, after induced with the inducer peptide, SppSIP. The color scheme is listed to the right of 
the histograms, revealing each sample represented by each colored histogram. All samples were 
induced with the inducer peptide, SppSIP before the cells reached the OD600 = 0.33. L. plantarum 
WCSF1 (black histogram) do not harbor any pSIP-derivative, and were induced before reached 
OD600 = 0.33 and incubated for 5 hours, not treated with lysozyme. 
 
 
 
 
 
 
 
 
APPENDIX 
vii 
 
 
 
 
 
 
 
Figure A7: Flow images revealing Lp_3014-TB displayed at the surfaces of L. plantarum 
cells, induced with the inducer peptide, SppSIP. The color scheme is listed to the right of the 
histograms, revealing each sample represented by each colored histogram. All samples were 
induced with the inducer peptide, SppSIP before the cells reached the OD600 = 0.33. The L. 
plantarum WCSF1 (black histogram) do not harbor any pSIP-derivative, and were induced before 
reached OD600 = 0.33 and incubated for 5 hours, not treated with lysozyme. 
